David Neal - Publications

Affiliations: 
2015- University of Oxford, Oxford, United Kingdom 

386 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Buhigas C, Warren AY, Leung WK, Whitaker HC, Luxton HJ, Hawkins S, Kay J, Butler A, Xu Y, Woodcock DJ, Merson S, Frame FM, Sahli A, Abascal F, Martincorena I, ... ... Neal DE, et al. The architecture of clonal expansions in morphologically normal tissue from cancerous and non-cancerous prostates. Molecular Cancer. 21: 183. PMID 36131292 DOI: 10.1186/s12943-022-01644-3  0.509
2022 Lane JA, Donovan JL, Young GJ, Davis M, Walsh EI, Avery KNL, Blazeby JM, Mason MD, Martin RM, Peters TJ, Turner EL, Wade J, Bollina P, Catto JWF, Doherty A, ... ... Neal DE, et al. Functional and quality of life outcomes of localised prostate cancer treatments (ProtecT study). Bju International. PMID 35373443 DOI: 10.1111/bju.15739  0.379
2022 Huynh-Le MP, Karunamuni R, Fan CC, Asona L, Thompson WK, Martinez ME, Eeles RA, Kote-Jarai Z, Muir KR, Lophatananon A, Schleutker J, Pashayan N, Batra J, Grönberg H, Neal DE, et al. Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score. Prostate Cancer and Prostatic Diseases. PMID 35152271 DOI: 10.1038/s41391-022-00497-7  0.499
2021 Huynh-Le MP, Fan CC, Karunamuni R, Thompson WK, Martinez ME, Eeles RA, Kote-Jarai Z, Muir K, Schleutker J, Pashayan N, Batra J, Grönberg H, Neal DE, Donovan JL, Hamdy FC, et al. Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. Nature Communications. 12: 1236. PMID 33623038 DOI: 10.1038/s41467-021-21287-0  0.499
2021 Emruli VK, Liljedahl L, Axelsson U, Richter C, Theorin L, Bjartell A, Lilja H, Donovan J, Neal D, Hamdy FC, Borrebaeck CAK. Identification of a serum biomarker signature associated with metastatic prostate cancer. Proteomics. Clinical Applications. e2000025. PMID 33580906 DOI: 10.1002/prca.202000025  0.485
2021 Conti DV, Darst BF, Moss LC, Saunders EJ, Sheng X, Chou A, Schumacher FR, Olama AAA, Benlloch S, Dadaev T, Brook MN, Sahimi A, Hoffmann TJ, Takahashi A, Matsuda K, ... ... Neal DE, et al. Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nature Genetics. PMID 33473200 DOI: 10.1038/s41588-021-00786-2  0.371
2021 Karlsson Q, Brook MN, Dadaev T, Wakerell S, Saunders EJ, Muir K, Neal DE, Giles GG, MacInnis RJ, Thibodeau SN, McDonnell SK, Cannon-Albright L, Teixeira MR, Paulo P, Cardoso M, et al. Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study. European Urology Oncology. PMID 33436325 DOI: 10.1016/j.euo.2020.12.001  0.466
2021 Karunamuni RA, Huynh-Le MP, Fan CC, Thompson W, Eeles RA, Kote-Jarai Z, Muir K, Lophatananon A, Schleutker J, Pashayan N, Batra J, Grönberg H, Walsh EI, ... ... Neal DE, et al. Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. Prostate Cancer and Prostatic Diseases. PMID 33420416 DOI: 10.1038/s41391-020-00311-2  0.412
2021 Conti DV, Darst BF, Moss LC, Saunders EJ, Sheng X, Chou A, Schumacher FR, Olama AAA, Benlloch S, Dadaev T, Brook MN, Sahimi A, Hoffmann TJ, Takahashi A, Matsuda K, ... ... Neal DE, et al. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nature Genetics. PMID 33398198 DOI: 10.1038/s41588-020-00748-0  0.418
2021 Sutton E, Lane JA, Davis M, Walsh EI, Neal DE, Hamdy FC, Mason M, Staffurth J, Martin RM, Metcalfe C, Peters TJ, Donovan JL, Wade J. Men's experiences of radiotherapy treatment for localized prostate cancer and its long-term treatment side effects: a longitudinal qualitative study. Cancer Causes & Control : Ccc. PMID 33394204 DOI: 10.1007/s10552-020-01380-3  0.449
2021 Eeles R, Giles G, Neal D, Hamdy F, Donovan J, Muir K, Easton D. SNPs in the kallikrein gene region associated with prostate cancer risk: true cause or association by design? Nature Genetics. 40. PMID 24409082 DOI: 10.1038/ng0908-1035  0.402
2020 Guldvik IJ, Zuber V, Braadland PR, Grytli HH, Ramberg H, Lilleby W, Thiede B, Zucknick M, Saatcioglu F, Gislefoss R, Kvåle R, George A, Grönberg H, Wiklund F, Neal DE, et al. Identification and Validation of Leucine-rich α-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification. European Urology Open Science. 21: 51-60. PMID 34337468 DOI: 10.1016/j.euros.2020.08.007  0.467
2020 Brandão A, Paulo P, Maia S, Pinheiro M, Peixoto A, Cardoso M, Silva MP, Santos C, Eeles RA, Kote-Jarai Z, Muir K, Ukgpcs Collaborators, Schleutker J, Wang Y, Pashayan N, ... ... Neal DE, et al. The Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor. Cancers. 12. PMID 33158149 DOI: 10.3390/cancers12113254  0.304
2020 Sanghera S, Mohiuddin S, Coast J, Garfield K, Noble S, Metcalfe C, Lane JA, Turner EL, Neal D, Hamdy FC, Martin RM, Donovan JL. Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial. Bmc Cancer. 20: 971. PMID 33028256 DOI: 10.1186/s12885-020-07276-4  0.42
2020 Wade J, Donovan J, Lane A, Davis M, Walsh E, Neal D, Turner E, Martin R, Metcalfe C, Peters T, Hamdy F, Kockelbergh R, Catto J, Paul A, Holding P, et al. Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial. Bmj Open. 10: e036024. PMID 32907896 DOI: 10.1136/bmjopen-2019-036024  0.475
2020 Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, Wade J, Noble S, Garfield K, Young G, Davis M, Peters TJ, Turner EL, Martin RM, Oxley J, ... ... Neal D, et al. Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT. Health Technology Assessment (Winchester, England). 24: 1-176. PMID 32773013 DOI: 10.3310/hta24370  0.53
2020 Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JMC, Papaemmanuil E, Brewer DS, Kallio HML, Hägnäs G, Annala M, Kivinummi K, Goody V, Latimer C, O'Meara S, Dawson KJ, ... ... Neal DE, et al. Author Correction: The evolutionary history of lethal metastatic prostate cancer. Nature. PMID 32728210 DOI: 10.1038/S41586-020-2581-5  0.468
2020 Noble SM, Garfield K, Lane JA, Metcalfe C, Davis M, Walsh EI, Martin RM, Turner EL, Peters TJ, Thorn JC, Mason M, Bollina P, Catto JWF, Doherty A, Gnanapragasam V, ... ... Neal DE, et al. The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer. British Journal of Cancer. PMID 32669672 DOI: 10.1038/s41416-020-0978-4  0.464
2020 Neal DE, Metcalfe C, Donovan JL, Lane JA, Davis M, Young GJ, Dutton SJ, Walsh EI, Martin RM, Peters TJ, Turner EL, Mason M, Bryant R, Bollina P, Catto J, et al. Erratum to 'Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received' [European Urology 77 (2020) 320-330]. European Urology. PMID 32624282 DOI: 10.1016/j.eururo.2020.05.030  0.438
2020 Huynh-Le MP, Fan CC, Karunamuni R, Walsh EI, Turner EL, Lane JA, Martin RM, Neal DE, Donovan JL, Hamdy FC, Parsons JKK, Eeles RA, Easton DF, Kote-Jarai Z, Amin Al Olama A, et al. A genetic risk score to personalize prostate cancer screening, applied to population data. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 32581112 DOI: 10.1158/1055-9965.Epi-19-1527  0.472
2020 Tran MGB, Bibby BAS, Yang L, Lo F, Warren AY, Shukla D, Osborne M, Hadfield J, Carroll T, Stark R, Scott H, Ramos-Montoya A, Massie C, Maxwell P, West CML, ... ... Neal DE, et al. Independence of HIF1a and androgen signaling pathways in prostate cancer. Bmc Cancer. 20: 469. PMID 32450824 DOI: 10.1186/S12885-020-06890-6  0.426
2020 Harrison S, Tilling K, Turner EL, Martin RM, Lennon R, Lane JA, Donovan JL, Hamdy FC, Neal DE, Bosch JLHR, Jones HE. Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen. Cancer Causes & Control : Ccc. PMID 32162172 DOI: 10.1007/s10552-020-01291-3  0.515
2020 Bryant RJ, Oxley J, Young GJ, Lane JA, Metcalfe C, Davis M, Turner EL, Martin RM, Goepel JR, Varma M, Griffiths DF, Grigor K, Mayer N, Warren AY, Bhattarai S, ... ... Neal DE, et al. The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression. Bju International. PMID 31900963 DOI: 10.1111/bju.14987  0.434
2019 Neal DE, Metcalfe C, Donovan JL, Lane JA, Davis M, Young GJ, Dutton SJ, Walsh EI, Martin RM, Peters TJ, Turner EL, Mason M, Bollina P, Catto J, Doherty A, et al. Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received. European Urology. PMID 31771797 DOI: 10.1016/j.eururo.2019.10.030  0.483
2019 Donovan JL, Opmeer B, Young GJ, Mills N, Martin RM, Lane JA, Metcalfe C, Peters TJ, Davis M, Turner EL, Walsh E, Neal DE, Hamdy FC. Factors associated with trial recruitment, preferences and treatments received were elucidated in a comprehensive-cohort study. Journal of Clinical Epidemiology. PMID 31170515 DOI: 10.1016/j.jclinepi.2019.05.036  0.357
2019 Leongamornlert DA, Saunders EJ, Wakerell S, Whitmore I, Dadaev T, Cieza-Borrella C, Benafif S, Brook MN, Donovan JL, Hamdy FC, Neal DE, Muir K, Govindasami K, Conti DV, Kote-Jarai Z, et al. Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel. European Urology. PMID 30777372 DOI: 10.1016/J.Eururo.2019.01.050  0.386
2019 Jiang X, Finucane HK, Schumacher FR, Schmit SL, Tyrer JP, Han Y, Michailidou K, Lesseur C, Kuchenbaecker KB, Dennis J, Conti DV, Casey G, Gaudet MM, Huyghe JR, Albanes D, ... ... Neal DE, et al. Shared heritability and functional enrichment across six solid cancers. Nature Communications. 10: 431. PMID 30683880 DOI: 10.1038/S41467-018-08054-4  0.316
2019 Matejcic M, Saunders EJ, Dadaev T, Brook MN, Wang K, Sheng X, Olama AAA, Schumacher FR, Ingles SA, Govindasami K, Benlloch S, Berndt SI, Albanes D, Koutros S, Muir K, ... ... Neal DE, et al. Author Correction: Germline variation at 8q24 and prostate cancer risk in men of European ancestry. Nature Communications. 10: 382. PMID 30655571 DOI: 10.1038/S41467-019-08293-Z  0.338
2019 Schumacher FR, Olama AAA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, Goh C, Brook MN, Sheng X, Fachal L, Dennis J, ... ... Neal DE, et al. Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nature Genetics. PMID 30622367 DOI: 10.1038/S41588-018-0330-6  0.355
2018 Jiang X, Dimou NL, Al-Dabhani K, Lewis SJ, Martin RM, Haycock PC, Gunter MJ, Key TJ, Eeles RA, Muir K, Neal D, Giles GG, Giovannucci EL, Stampfer M, Pierce BL, et al. Circulating vitamin D concentrations and risk of breast and prostate cancer: a Mendelian randomization study. International Journal of Epidemiology. PMID 30597039 DOI: 10.1093/Ije/Dyy284  0.398
2018 Travis RC, Perez-Cornago A, Appleby PN, Albanes D, Joshu CE, Lutsey PL, Mondul AM, Platz EA, Weinstein SJ, Layne TM, Helzlsouer KJ, Visvanathan K, Palli D, Peeters PH, Bueno-de-Mesquita B, ... ... Neal DE, et al. A collaborative analysis of individual participant data from 19 prospective studies assesses circulating vitamin D and prostate cancer risk. Cancer Research. PMID 30425058 DOI: 10.1158/0008-5472.Can-18-2318  0.411
2018 Matejcic M, Saunders EJ, Dadaev T, Brook MN, Wang K, Sheng X, Olama AAA, Schumacher FR, Ingles SA, Govindasami K, Benlloch S, Berndt SI, Albanes D, Koutros S, Muir K, ... ... Neal DE, et al. Germline variation at 8q24 and prostate cancer risk in men of European ancestry. Nature Communications. 9: 4616. PMID 30397198 DOI: 10.1038/S41467-018-06863-1  0.438
2018 Adams C, Richmond RC, Santos Ferreira DL, Spiller W, Tan VY, Zheng J, Wurtz P, Donovan JL, Hamdy FC, Neal DE, Lane JA, Davey Smith G, Relton CL, Eeles RA, Henderson BE, et al. Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 30352818 DOI: 10.1158/1055-9965.Epi-18-0079  0.527
2018 Lane JA, Er V, Avery KNL, Horwood J, Cantwell M, Caro GP, Crozier A, Davey Smith G, Donovan JL, Down L, Hamdy FC, Gillatt D, Holly J, Macefield R, Moody H, ... Neal DE, et al. ProDiet: A Phase II Randomized Placebo-Controlled Trial of Green Tea Catechins and Lycopene in Men at Increased Risk of Prostate Cancer. Cancer Prevention Research (Philadelphia, Pa.). PMID 30309839 DOI: 10.1158/1940-6207.CAPR-18-0147  0.44
2018 Warren AY, Massie CE, Watt K, Luko K, Orafidiya F, Selth LA, Mohammed H, Chohan BS, Menon S, Baridi A, Zhao W, Escriu C, Pungsrinont T, D'Santos C, Yang X, ... ... Neal DE, et al. A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer. Oncogene. PMID 30237440 DOI: 10.1038/S41388-018-0501-Z  0.314
2018 Dadaev T, Saunders EJ, Newcombe PJ, Anokian E, Leongamornlert DA, Brook MN, Cieza-Borrella C, Mijuskovic M, Wakerell S, Olama AAA, Schumacher FR, Berndt SI, Benlloch S, Ahmed M, Goh C, ... ... Neal DE, et al. Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nature Communications. 9: 2256. PMID 29892050 DOI: 10.1038/S41467-018-04109-8  0.453
2018 Yang L, Roberts D, Takhar M, Erho N, Bibby BAS, Thiruthaneeswaran N, Bhandari V, Cheng WC, Haider S, McCorry AMB, McArt D, Jain S, Alshalalfa M, Ross A, Schaffer E, ... ... Neal DE, et al. Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer. Ebiomedicine. PMID 29729848 DOI: 10.1016/J.Ebiom.2018.04.019  0.648
2018 Wedge DC, Gundem G, Mitchell T, Woodcock DJ, Martincorena I, Ghori M, Zamora J, Butler A, Whitaker H, Kote-Jarai Z, Alexandrov LB, Van Loo P, Massie CE, Dentro S, Warren AY, ... ... Neal DE, et al. Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. Nature Genetics. PMID 29662167 DOI: 10.1038/S41588-018-0086-Z  0.484
2018 Martin RM, Donovan JL, Turner EL, Metcalfe C, Young GJ, Walsh EI, Lane JA, Noble S, Oliver SE, Evans S, Sterne JAC, Holding P, Ben-Shlomo Y, Brindle P, Williams NJ, ... ... Neal DE, et al. Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial. Jama. 319: 883-895. PMID 29509864 DOI: 10.1001/jama.2018.0154  0.683
2018 Gilbert R, Tilling K, Martin RM, Lane JA, Davis M, Hamdy FC, Neal DE, Donovan JL, Metcalfe C. Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer. Cancer Causes & Control : Ccc. PMID 29453511 DOI: 10.1007/s10552-018-1014-3  0.504
2018 Lophatananon A, Stewart-Brown S, Kote-Jarai Z, Al Olama AA, Garcia SB, Neal DE, Hamdy FC, Donovan JL, Giles GG, Fitzgerald LM, Southey MC, Pharoah P, Pashayan N, Gronberg H, Wiklund F, et al. Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium. British Journal of Cancer. PMID 29438364 DOI: 10.1038/bjc.2018.6  0.409
2018 Saunders EJ, Dadaev T, Leongamornlert DA, Al Olama AA, Benlloch S, Giles GG, Wiklund F, Grönberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Neal D, Pasayan N, Khaw KT, et al. Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array. British Journal of Cancer. PMID 29438362 DOI: 10.1038/bjc.2017.468  0.338
2018 Jurmeister S, Ramos-Montoya A, Sandi C, Pértega-Gomes N, Wadhwa K, Lamb AD, Dunning MJ, Attig J, Carroll JS, Fryer LG, Felisbino SL, Neal DE. Identification of potential therapeutic targets in prostate cancer through a cross-species approach. Embo Molecular Medicine. PMID 29437778 DOI: 10.15252/emmm.201708274  0.461
2018 Vickers A, Vertosick EA, Sjoberg DD, Hamdy F, Neal D, Bjartell A, Hugosson J, Donovan JL, Villers A, Zappala S, Lilja H. Value of Intact Prostate Specific Antigen and Human Kallikrein 2 in the 4 Kallikrein Predictive Model: An Individual Patient Data Meta-Analysis. The Journal of Urology. PMID 29366640 DOI: 10.1016/j.juro.2018.01.070  0.474
2018 Watson EK, Shinkins B, Matheson L, Burns RM, Frith E, Neal D, Hamdy F, Walter FM, Weller D, Wilkinson C, Faithfull S, Sooriakumaran P, Kastner C, Campbell C, Neal RD, et al. Supporting prostate cancer survivors in primary care: Findings from a pilot trial of a nurse-led psycho-educational intervention (PROSPECTIV). European Journal of Oncology Nursing : the Official Journal of European Oncology Nursing Society. 32: 73-81. PMID 29353635 DOI: 10.1016/j.ejon.2017.12.002  0.324
2018 Seibert TM, Fan CC, Wang Y, Zuber V, Karunamuni R, Parsons JK, Eeles RA, Easton DF, Kote-Jarai Z, Al Olama AA, Garcia SB, Muir K, Grönberg H, Wiklund F, Aly M, ... ... Neal DE, et al. Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. Bmj (Clinical Research Ed.). 360: j5757. PMID 29321194 DOI: 10.1136/Bmj.J5757  0.431
2018 Matejcic M, Saunders EJ, Dadaev T, Brook M, Olama AAA, Schumacher FR, Berndt SI, Benlloch S, Muir K, Govindasami K, Stevens VL, Gapstur SM, Tangen CM, Batra J, Clements J, ... ... Neal DE, et al. Abstract 227: Germline variation at 8q24 and prostate cancer risk in men of European ancestry Epidemiology. DOI: 10.1158/1538-7445.Am2018-227  0.461
2018 Bibby B, Tran M, Yang L, Lo F, Warren A, Shukla D, Osborne M, Hadfield J, Carroll T, Stark R, Scott H, Ramos-Montoya A, Massie C, Maxwell P, West C, ... ... Neal D, et al. EP-2298: Hypoxia inducible factor 1α confers androgen independence in prostate cancer Radiotherapy and Oncology. 127. DOI: 10.1016/S0167-8140(18)32607-0  0.455
2018 Carmona Echeverria L, Johnston T, Rosenfeld A, Eldridge M, Vowler S, George A, Corcoran M, Burge J, Stearn S, Massie C, Neal D, Heavey S, Pye H, Ahmed HU, Emberton M, et al. PD60-02 DISCOVERY AND VALIDATION OF A NOVEL FLUID BIOMARKER FOR THE DIAGNOSIS AND RISK STRATIFICATION OF PROSTATE CANCER Journal of Urology. 199. DOI: 10.1016/J.JURO.2018.02.2814  0.371
2018 Patel K, Massie C, Marass F, Morris J, Lynch A, Mouliere F, Neal D, Gnanapragasam V, Forshew T, Rosenfeld N. PD56-03 DETECTION OF PRIVATE CLONAL MUTATIONS IN LOCALISED PROSTATE CANCER FROM RARE MOLECULES OF CIRCULATING TUMOUR DNA Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.2635  0.338
2017 Donovan JL, Young GJ, Walsh EI, Metcalfe C, Lane JA, Martin RM, Tazewell MK, Davis M, Peters TJ, Turner EL, Mills N, Khazragui H, Khera TK, Neal DE, Hamdy FC, et al. A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial. Journal of Clinical Epidemiology. PMID 29288137 DOI: 10.1016/j.jclinepi.2017.12.019  0.462
2017 Leal J, Welton NJ, Martin RM, Donovan J, Hamdy F, Neal D, Noble S, Lane A, Wolstenholme J. Estimating the sensitivity of a prostate cancer screening programme for different PSA cut-off levels: A UK case study. Cancer Epidemiology. 52: 99-105. PMID 29278842 DOI: 10.1016/j.canep.2017.12.002  0.466
2017 Merriel SWD, Turner EL, Walsh E, Young GJ, Metcalfe C, Hounsome L, Tudge I, Donovan J, Hamdy F, Neal D, Martin RM. Cross-sectional study evaluating data quality of the National Cancer Registration and Analysis Service (NCRAS) prostate cancer registry data using the Cluster randomised trial of PSA testing for Prostate cancer (CAP). Bmj Open. 7: e015994. PMID 29138196 DOI: 10.1136/bmjopen-2017-015994  0.511
2017 Young GJ, Harrison S, Turner EL, Walsh EI, Oliver SE, Ben-Shlomo Y, Evans S, Lane JA, Neal DE, Hamdy FC, Donovan JL, Martin RM, Metcalfe C. Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study. Bmj Open. 7: e017729. PMID 29084797 DOI: 10.1136/bmjopen-2017-017729  0.407
2017 Asim M, Tarish F, Zecchini HI, Sanjiv K, Gelali E, Massie CE, Baridi A, Warren AY, Zhao W, Ogris C, McDuffus LA, Mascalchi P, Shaw G, Dev H, Wadhwa K, ... ... Neal D, et al. Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. Nature Communications. 8: 374. PMID 28851861 DOI: 10.1038/S41467-017-00393-Y  0.5
2017 Lophatananon A, Stewart-Brown S, Kote-Jarai Z, Olama AAA, Garcia SB, Neal DE, Hamdy FC, Donovan JL, Giles GG, Fitzgerald LM, Southey MC, Pharoah P, Pashayan N, Gronberg H, Wiklund F, et al. Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium. British Journal of Cancer. PMID 28765617 DOI: 10.1038/Bjc.2017.231  0.492
2017 Luca BA, Brewer DS, Edwards DR, Edwards S, Whitaker HC, Merson S, Dennis N, Cooper RA, Hazell S, Warren AY, Eeles R, Lynch AG, Ross-Adams H, Lamb AD, ... Neal DE, et al. DESNT: A Poor Prognosis Category of Human Prostate Cancer. European Urology Focus. PMID 28753852 DOI: 10.1016/J.Euf.2017.01.016  0.507
2017 Er V, Biernacka K, Simpkin AJ, Martin RM, Jeffreys M, Emmett P, Gilbert R, Avery KNL, Walsh E, Davis M, Donovan JL, Neal DE, Hamdy FC, Holly JMP, Lane JA. Post-diagnosis serum insulin-like growth factors in relation to dietary and lifestyle changes in the Prostate testing for cancer and Treatment (ProtecT) trial. Cancer Causes & Control : Ccc. PMID 28646365 DOI: 10.1007/s10552-017-0910-2  0.403
2017 Walker SM, Knight LA, McCavigan AM, Logan GE, Berge V, Sherif A, Pandha H, Warren AY, Davidson C, Uprichard A, Blayney JK, Price B, Jellema GL, Steele CJ, Svindland A, ... ... Neal DE, et al. Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology. European Urology. PMID 28408174 DOI: 10.1016/j.eururo.2017.03.027  0.513
2017 Ross-Adams H, Lamb AD, Dunning MJ, Halim S, Lindberg J, Massie CM, Egevad LA, Russell R, Ramos-Montoya A, Vowler SL, Sharma NL, Kay J, Whitaker H, Clark J, Hurst R, ... ... Neal DE, et al. Corrigendum to "Integration of Copy Number and Transcriptomics Provides Risk Stratification in Prostate Cancer: A Discovery and Validation Cohort Study" [EBioMedicine 2 (9) (2015) 1133-1144]. Ebiomedicine. PMID 28292578 DOI: 10.1016/j.ebiom.2017.03.010  0.471
2017 Rochette A, Boufaied N, Scarlata E, Hamel L, Brimo F, Whitaker HC, Ramos-Montoya A, Neal DE, Dragomir A, Aprikian A, Chevalier S, Thomson AA. Asporin is a stromally expressed marker associated with prostate cancer progression. British Journal of Cancer. PMID 28152543 DOI: 10.1038/Bjc.2017.15  0.472
2017 Hamdy FC, Donovan JL, Neal DE. 10-Year Outcomes in Localized Prostate Cancer. The New England Journal of Medicine. 376: 180. PMID 28076716 DOI: 10.1056/NEJMc1614342  0.468
2017 Hori S, Wadhwa K, Pisupati V, Zecchini V, Ramos-Montoya A, Warren AY, Neal DE, Gnanapragasam VJ. Loss of hSef promotes metastasis through up-regulation of EMT in prostate cancer. International Journal of Cancer. PMID 28073170 DOI: 10.1002/ijc.30604  0.33
2017 Jain S, Lyons C, Walker SM, McQuaid S, Hynes S, Mitchell DM, Pang B, Logan GE, McCavigan A, O'Rourke D, Davidson CJ, Knight LA, Berge V, Neal D, Pandha HS, et al. A metastatic biology gene expression assay to predict the risk of distant metastases in patients with localized prostate cancer treated with primary radical treatment. Journal of Clinical Oncology. 35: 11-11. DOI: 10.1200/JCO.2017.35.6_SUPPL.11  0.325
2017 Guldvik I, Grytli H, Zuber V, Thiede B, Saatcioglu F, Gislefoss R, Kvåle R, George A, Gnanapragasam V, Grönberg H, Wiklund F, Neal D, Mills I, Taskén K A. Identification and validation of a novel blood-based biomarker of aggressive prostate cancer European Urology Supplements. 16: e1083. DOI: 10.1016/S1569-9056(17)30682-6  0.469
2017 Johnston T, Lamb A, Vowler S, Xiong T, Moore A, Holding P, Herbert P, Davis M, Lane A, Donovan J, Hamdy F, Neal D. An evaluation of a selective prostate cancer screening program using family history as a supplementary screening tool to PSA: Results from the ProtecT trial European Urology Supplements. 16: e404-e405. DOI: 10.1016/S1569-9056(17)30299-3  0.393
2017 Jain S, Lyons C, Walker S, McQuaid S, Hynes S, Mitchell D, Pang B, Logan G, McCavigan A, O'Rourke D, Davidson C, Knight L, Sheriff A, Berge V, Neal D, et al. OC-0126: A gene expression assay to predict the risk of distant metastases in localized prostate cancer Radiotherapy and Oncology. 123: S59. DOI: 10.1016/S0167-8140(17)30569-8  0.434
2017 Lane J, Er V, Horwood J, Avery K, Holly J, Martin R, Neal D, Hamdy F, Donovan J, Metcalfe C. A randomized controlled feasibility trial of green tea and lycopene interventions in men at elevated risk of prostate cancer (ProDiet) European Journal of Surgical Oncology. 43: 2236. DOI: 10.1016/j.ejso.2017.10.179  0.453
2016 Harrison S, Tilling K, Turner EL, Lane JA, Simpkin A, Davis M, Donovan J, Hamdy FC, Neal DE, Martin RM. Investigating the prostate specific antigen, body mass index and age relationship: is an age-BMI-adjusted PSA model clinically useful? Cancer Causes & Control : Ccc. PMID 27830401 DOI: 10.1007/s10552-016-0827-1  0.398
2016 Lalonde E, Alkallas R, Chua ML, Fraser M, Haider S, Meng A, Zheng J, Yao CQ, Picard V, Orain M, Hovington H, Murgic J, Berlin A, Lacombe L, Bergeron A, ... ... Neal DE, et al. Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors. European Urology. PMID 27815082 DOI: 10.1016/J.Eururo.2016.10.013  0.612
2016 Taylor AE, Martin RM, Geybels MS, Stanford JL, Shui I, Eeles R, Easton D, Kote-Jarai Z, Al Olama AA, Benlloch S, Muir K, Giles GG, Wiklund F, Gronberg H, Haiman CA, ... ... Neal D, et al. Investigating the possible causal role of coffee consumption with prostate cancer risk and progression using Mendelian randomization analysis. International Journal of Cancer. PMID 27741566 DOI: 10.1002/Ijc.30462  0.476
2016 Walsh EI, Turner EL, Lane JA, Donovan JL, Neal DE, Hamdy FC, Martin RM. Characteristics of men responding to an invitation to undergo testing for prostate cancer as part of a randomised trial. Trials. 17: 497. PMID 27737692 DOI: 10.1186/s13063-016-1624-6  0.533
2016 Ross-Adams H, Ball S, Lawrenson K, Halim S, Russell R, Wells C, Strand SH, Ørntoft TF, Larson M, Armasu S, Massie CE, Asim M, Mortensen MM, Borre M, Woodfine K, ... ... Neal DE, et al. HNF1B variants associate with promoter methylation and regulate gene networks activated in prostate and ovarian cancer. Oncotarget. PMID 27732966 DOI: 10.18632/Oncotarget.12543  0.391
2016 Johnston TJ, Shaw GL, Lamb AD, Parashar D, Greenberg D, Xiong T, Edwards AL, Gnanapragasam V, Holding P, Herbert P, Davis M, Mizielinsk E, Lane JA, Oxley J, Robinson M, ... ... Neal DE, et al. Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial. European Urology. PMID 27720537 DOI: 10.1016/j.eururo.2016.09.040  0.519
2016 Vickers A, Vertosick EA, Sjoberg DD, Roobol MJ, Hamdy F, Neal D, Bjartell A, Hugosson J, Donovan JL, Villers A, Zappala S, Lilja H. Properties of the four kallikrein panel outside the diagnostic grey zone: meta-analysis of patients with positive digital rectal exam or prostate-specific antigen 10 ng / mL and above. The Journal of Urology. PMID 27693450 DOI: 10.1016/j.juro.2016.09.086  0.436
2016 Lane JA, Oliver SE, Appleby PN, Lentjes MA, Emmett P, Kuh D, Stephen A, Brunner EJ, Shipley MJ, Hamdy FC, Neal DE, Donovan JL, Khaw KT, Key TJ. Prostate cancer risk related to foods, food groups, macronutrients and micronutrients derived from the UK Dietary Cohort Consortium food diaries. European Journal of Clinical Nutrition. PMID 27677361 DOI: 10.1038/ejcn.2016.162  0.333
2016 Brunner C, Davies NM, Martin RM, Eeles R, Easton D, Kote-Jarai Z, Al Olama AA, Benlloch S, Muir K, Giles G, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, ... ... Neal D, et al. Alcohol Consumption and Prostate Cancer Incidence and Progression: A Mendelian Randomization Study. International Journal of Cancer. PMID 27643404 DOI: 10.1002/Ijc.30436  0.474
2016 Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, Blazeby JM, Peters TJ, Holding P, Bonnington S, Lennon T, Bradshaw L, Cooper D, Herbert P, Howson J, ... ... Neal DE, et al. Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. The New England Journal of Medicine. PMID 27626365 DOI: 10.1056/NEJMoa1606221  0.329
2016 Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, Davis M, Peters TJ, Turner EL, Martin RM, Oxley J, Robinson M, Staffurth J, Walsh E, Bollina P, ... ... Neal DE, et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. The New England Journal of Medicine. PMID 27626136 DOI: 10.1056/NEJMoa1606220  0.402
2016 Thomas B, Kay J, Menon S, Vowler S, Dawson S, Bucklow L, Luxton H, Johnston T, Massie C, Pugh M, Warren AY, Barker P, Burling K, Lynch AG, George A, ... ... Neal D, et al. Whole blood mRNA in prostate cancer reveals a 4-gene androgen regulated panel. Endocrine-Related Cancer. PMID 27578825 DOI: 10.1530/ERC-16-0287  0.391
2016 Kar SP, Beesley J, Amin Al Olama A, Michailidou K, Tyrer J, Kote-Jarai Z, Lawrenson K, Lindstrom S, Ramus SJ, Thompson DJ, Kibel AS, Dansonka-Mieszkowska A, Michael A, Dieffenbach AK, ... ... Neal DE, et al. Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discovery. PMID 27432226 DOI: 10.1158/2159-8290.Cd-15-1227  0.359
2016 Madhu B, Shaw GL, Warren AY, Neal DE, Griffiths JR. Response of Degarelix treatment in human prostate cancer monitored by HR-MAS (1)H NMR spectroscopy. Metabolomics : Official Journal of the Metabolomic Society. 12: 120. PMID 27429605 DOI: 10.1007/s11306-016-1055-0  0.484
2016 Mason MD, Moore R, Jones G, Lewis G, Donovan JL, Neal DE, Hamdy FC, Lane JA, Staffurth JN. Radiotherapy for Prostate Cancer: is it 'what you do' or 'the way that you do it'? A UK Perspective on Technique and Quality Assurance. Clinical Oncology (Royal College of Radiologists (Great Britain)). PMID 27425582 DOI: 10.1016/j.clon.2016.05.011  0.477
2016 Lane JA, Metcalfe C, Young GJ, Peters TJ, Blazeby J, Avery K, Dedman D, Down L, Mason MD, Neal DE, Hamdy FC, Donovan JL. Patient-reported outcomes in the ProtecT randomised trial of clinically localised prostate cancer treatments: design and baseline urinary, bowel and sexual function and quality of life. Bju International. PMID 27415448 DOI: 10.1111/bju.13582  0.487
2016 Neal D, Lilja H. Circulating Tumor Cell Count as an Indicator of Treatment Benefit in Advanced Prostate Cancer. European Urology. PMID 27344293 DOI: 10.1016/j.eururo.2016.06.014  0.448
2016 Asim M, Massie CE, Neal DE. Kinase joins the chaperone club: Androgen-regulated kinome reveals choline kinase alpha as a potential drug target in prostate cancer. Molecular & Cellular Oncology. 3: e1140262. PMID 27314091 DOI: 10.1080/23723556.2016.1140262  0.418
2016 Turner EL, Metcalfe C, Donovan JL, Noble S, Sterne JA, Lane JA, I Walsh E, Hill EM, Down L, Ben-Shlomo Y, Oliver SE, Evans S, Brindle P, Williams NJ, Hughes LJ, ... ... Neal DE, et al. Contemporary accuracy of death certificates for coding prostate cancer as a cause of death: Is reliance on death certification good enough? A comparison with blinded review by an independent cause of death evaluation committee. British Journal of Cancer. 115: 90-4. PMID 27253172 DOI: 10.1038/bjc.2016.162  0.678
2016 Bonilla C, Lewis SJ, Rowlands MA, Gaunt TR, Davey Smith G, Gunnell D, Palmer T, Donovan JL, Hamdy FC, Neal DE, Eeles R, Easton D, Kote-Jarai Z, Al Olama AA, Benlloch S, et al. Assessing the role of insulin-like growth factors and binding proteins in prostate cancer using Mendelian randomization: Genetic variants as instruments for circulating levels. International Journal of Cancer. 139: 1520-33. PMID 27225428 DOI: 10.1002/Ijc.30206  0.342
2016 Castro E, Mikropoulos C, Bancroft EK, Dadaev T, Goh C, Taylor N, Saunders E, Borley N, Keating D, Page EC, Saya S, Hazell S, Livni N, deSouza N, Neal D, et al. The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer. The Oncologist. PMID 27151655 DOI: 10.1634/theoncologist.2015-0336  0.409
2016 Price AJ, Travis RC, Appleby PN, Albanes D, Barricarte Gurrea A, Bjørge T, Bueno-de-Mesquita HB, Chen C, Donovan J, Gislefoss R, Goodman G, Gunter M, Hamdy FC, Johansson M, King IB, ... ... Neal DE, et al. Circulating Folate and Vitamin B12 and Risk of Prostate Cancer: A Collaborative Analysis of Individual Participant Data from Six Cohorts Including 6875 Cases and 8104 Controls. European Urology. PMID 27061263 DOI: 10.1016/J.Eururo.2016.03.029  0.422
2016 Gusev A, Shi H, Kichaev G, Pomerantz M, Li F, Long HW, Ingles SA, Kittles RA, Strom SS, Rybicki BA, Nemesure B, Isaacs WB, Zheng W, Pettaway CA, Yeboah ED, ... ... Neal DE, et al. Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. Nature Communications. 7: 10979. PMID 27052111 DOI: 10.1038/Ncomms10979  0.381
2016 Bonilla C, Lewis SJ, Martin RM, Donovan JL, Hamdy FC, Neal DE, Eeles R, Easton D, Kote-Jarai Z, Al Olama AA, Benlloch S, Muir K, Giles GG, Wiklund F, Gronberg H, et al. Pubertal development and prostate cancer risk: Mendelian randomization study in a population-based cohort. Bmc Medicine. 14: 66. PMID 27044414 DOI: 10.1186/S12916-016-0602-X  0.442
2016 Bull CJ, Bonilla C, Holly JM, Perks CM, Davies N, Haycock P, Yu OH, Richards JB, Eeles R, Easton D, Kote-Jarai Z, Amin Al Olama A, Benlloch S, Muir K, Giles GG, ... ... Neal D, et al. Blood lipids and prostate cancer: a Mendelian randomization analysis. Cancer Medicine. 5: 1125-36. PMID 26992435 DOI: 10.1002/Cam4.695  0.428
2016 Saunders EJ, Dadaev T, Leongamornlert DA, Olama AA, Benlloch S, Giles GG, Wiklund F, Grönberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Neal D, Pasayan N, Khaw KT, et al. Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array. British Journal of Cancer. PMID 26964030 DOI: 10.1038/Bjc.2016.50  0.372
2016 Whitington T, Gao P, Song W, Ross-Adams H, Lamb AD, Yang Y, Svezia I, Klevebring D, Mills IG, Karlsson R, Halim S, Dunning MJ, Egevad L, Warren AY, Neal DE, et al. Gene regulatory mechanisms underpinning prostate cancer susceptibility. Nature Genetics. PMID 26950096 DOI: 10.1038/ng.3523  0.389
2016 Travis RC, Appleby PN, Martin RM, Holly JM, Albanes D, Black A, Bueno-de-Mesquita HB, Chan JM, Chen C, Chirlaque MD, Cook MB, Deschasaux M, Donovan JL, Ferrucci L, Galan P, ... ... Neal DE, et al. A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk. Cancer Research. 76: 2288-300. PMID 26921328 DOI: 10.1158/0008-5472.Can-15-1551  0.462
2016 Marzec J, Mao X, Li M, Wang M, Feng N, Gou X, Wang G, Sun Z, Xu J, Xu H, Zhang X, Zhao SC, Ren G, Yu Y, Wu Y, ... ... Neal DE, et al. A genetic study and meta-analysis of the genetic predisposition of prostate cancer in a Chinese population. Oncotarget. PMID 26881390 DOI: 10.18632/oncotarget.7250  0.481
2016 Simpkin AJ, Donovan JL, Tilling K, Lane JA, Martin RM, Albertsen PC, Bill-Axelson A, Carter HB, Bosch R, Ferrucci L, Hamdy FC, Holmberg L, Metter EJ, Neal DE, Parker CC, et al. Prostate specific antigen patterns in US and European populations: comparison of six diverse cohorts. Bju International. PMID 26799945 DOI: 10.1111/bju.13422  0.453
2016 Stacey SN, Kehr B, Gudmundsson J, Zink F, Jonasdottir A, Gudjonsson SA, Sigurdsson A, Halldorsson BV, Agnarsson BA, Benediktsdottir KR, Aben KK, Vermeulen SH, Cremers RG, Panadero A, Helfand BT, ... ... Neal DE, et al. Insertion of an SVA-E retrotransposon into the CASP8 gene is associated with protection against prostate cancer. Human Molecular Genetics. PMID 26740556 DOI: 10.1093/Hmg/Ddv622  0.34
2016 Asim M, Massie CE, Orafidiya F, Pértega-Gomes N, Warren AY, Esmaeili M, Selth LA, Zecchini HI, Luko K, Qureshi A, Baridi A, Menon S, Madhu B, Escriu C, Lyons S, ... ... Neal DE, et al. Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target. Journal of the National Cancer Institute. 108. PMID 26657335 DOI: 10.1093/Jnci/Djv371  0.436
2016 Asim M, Zecchini H, Tarish F, Massie C, Baridi A, Warren A, Zhao W, McDuffus L, Mascalchi P, Shaw G, Dev H, Wadhwa K, Wijnhoven P, Forment J, Lyons S, ... ... Neal D, et al. Abstract LB-176: The human androgen receptor regulates DNA damage response (DDR) in prostate cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-176  0.413
2016 Asim M, Massie C, Warren A, Luko K, Chohan B, Menon S, Baridi A, Orafidiya F, Zhao W, Escriu C, Mohammed H, D’Santos C, Yang X, Taylor C, Qureshi A, ... ... Neal D, et al. Abstract LB-003: Androgen-regulated proteome reveals a therapeutically relevant androgen receptor coactivator target in prostate cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-003  0.418
2016 Wadhwa K, Bon H, Holmes K, Warren A, Whittaker H, Kay J, Fryer L, Neal D, Gnanapragasam V, Carroll J. 1067 SIK2 is a novel secreted protein associated with a malignant phenotype in prostate cancer European Urology Supplements. 15: e1067. DOI: 10.1016/S1569-9056(16)61068-0  0.484
2016 Johnston T, Shaw G, Lamb A, Gnanapragasam V, Greenberg D, Parashar D, Xiong T, Moore A, Holding P, Herbert P, Davis M, Down E, Lane J, Donovan J, Hamdy F, ... Neal D, et al. 95 Detection of asymptomatic locally advanced and high-risk prostate cancer through PSA testing: Clinical outcomes in men excluded from the ProtecT Trial European Urology Supplements. 15: e95. DOI: 10.1016/S1569-9056(16)60097-0  0.466
2016 Merriel SWD, Turner EL, Walsh E, Young G, Metcalfe C, Hounsome L, Tudge I, Donovan J, Hamdy F, Neal D, Martin RM. Validation of the National Cancer Registration and Analysis Service prostate cancer registry with data from the CAP study The Lancet. 388: S77. DOI: 10.1016/S0140-6736(16)32313-3  0.465
2016 Vickers A, Sjoberg D, Vertosick E, Roobol M, Hamdy F, Bjartell A, Neal D, Donovan J, Lilja H. MP39-09 PROPERTIES OF THE FOUR KALLIKREIN PANEL FOR PREDICTION OF PROSTATE BIOPSY OUTCOME IN MEN WITH HIGH PSA (10-25 NG /ML) Journal of Urology. 195. DOI: 10.1016/j.juro.2016.02.134  0.37
2015 Shaw GL, Whitaker H, Corcoran M, Dunning MJ, Luxton H, Kay J, Massie CE, Miller JL, Lamb AD, Ross-Adams H, Russell R, Nelson AW, Eldridge MD, Lynch AG, Ramos-Montoya A, ... ... Neal DE, et al. The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer. European Urology. PMID 26572708 DOI: 10.1016/j.eururo.2015.10.042  0.339
2015 Key TJ, Appleby PN, Travis RC, Albanes D, Alberg AJ, Barricarte A, Black A, Boeing H, Bueno-de-Mesquita HB, Chan JM, Chen C, Cook MB, Donovan JL, Galan P, Gilbert R, ... ... Neal DE, et al. Carotenoids, retinol, tocopherols, and prostate cancer risk: pooled analysis of 15 studies. The American Journal of Clinical Nutrition. 102: 1142-57. PMID 26447150 DOI: 10.3945/Ajcn.115.114306  0.476
2015 Gilbert R, Martin RM, Evans DM, Tilling K, Davey Smith G, Kemp JP, Lane JA, Hamdy FC, Neal DE, Donovan JL, Metcalfe C. Incorporating Known Genetic Variants Does Not Improve the Accuracy of PSA Testing to Identify High Risk Prostate Cancer on Biopsy. Plos One. 10: e0136735. PMID 26431041 DOI: 10.1371/journal.pone.0136735  0.452
2015 Davies NM, Gaunt TR, Lewis SJ, Holly J, Donovan JL, Hamdy FC, Kemp JP, Eeles R, Easton D, Kote-Jarai Z, Al Olama AA, Benlloch S, Muir K, Giles GG, Wiklund F, ... ... Neal D, et al. The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium. Cancer Causes & Control : Ccc. 26: 1603-16. PMID 26387087 DOI: 10.1007/S10552-015-0654-9  0.481
2015 Wade J, Holding PN, Bonnington S, Rooshenas L, Lane JA, Salter CE, Tilling K, Speakman MJ, Brewster SF, Evans S, Neal DE, Hamdy FC, Donovan JL. Establishing nurse-led active surveillance for men with localised prostate cancer: development and formative evaluation of a model of care in the ProtecT trial. Bmj Open. 5: e008953. PMID 26384727 DOI: 10.1136/bmjopen-2015-008953  0.323
2015 Szulkin R, Karlsson R, Whitington T, Aly M, Gronberg H, Eeles RA, Easton DF, Kote-Jarai Z, Amin Al Olama A, Benlloch S, Muir K, Giles GG, Southey MC, FitzGerald L, Henderson BE, ... ... Neal D, et al. Genome-wide association study of prostate cancer-specific survival. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 26307654 DOI: 10.1158/1055-9965.Epi-15-0543  0.478
2015 Szulkin R, Whitington T, Eklund M, Aly M, Eeles RA, Easton D, Kote-Jarai Z, Amin Al Olama A, Benlloch S, Muir K, Giles GG, Southey MC, Fitzgerald LM, Henderson BE, Schumacher F, ... ... Neal DE, et al. Prediction of individual genetic risk to prostate cancer using a polygenic score. The Prostate. 75: 1467-1474. PMID 26177737 DOI: 10.1002/Pros.23037  0.484
2015 Pertega-Gomes N, Vizcaino JR, Felisbino S, Warren AY, Shaw G, Kay J, Whitaker H, Lynch AG, Fryer L, Neal DE, Massie CE. Epigenetic and oncogenic regulation of SLC16A7 (MCT2) results in protein over-expression, impacting on signalling and cellular phenotypes in prostate cancer. Oncotarget. PMID 26035357 DOI: 10.18632/ONCOTARGET.4328  0.316
2015 Cooper CS, Eeles R, Wedge DC, Van Loo P, Gundem G, Alexandrov LB, Kremeyer B, Butler A, Lynch AG, Camacho N, Massie CE, Kay J, Luxton HJ, Edwards S, Kote-Jarai Z, ... ... Neal DE, et al. Corrigendum: Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nature Genetics. 47: 689. PMID 26018901 DOI: 10.1038/Ng0615-689B  0.478
2015 Wade J, Rosario DJ, Howson J, Avery KN, Salter CE, Goodwin ML, Blazeby JM, Lane JA, Metcalfe C, Neal DE, Hamdy FC, Donovan JL. Role of information in preparing men for transrectal ultrasound guided prostate biopsy: a qualitative study embedded in the ProtecT trial. Bmc Health Services Research. 15: 80. PMID 25889315 DOI: 10.1186/s12913-015-0729-z  0.41
2015 Pertega-Gomes N, Felisbino S, Massie CE, Vizcaino JR, Coelho R, Sandi C, Simoes-Sousa S, Jurmeister S, Ramos-Montoya A, Asim M, Tran M, Oliveira E, Lobo da Cunha A, Maximo V, Baltazar F, ... Neal DE, et al. A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy. The Journal of Pathology. 236: 517-30. PMID 25875424 DOI: 10.1002/path.4547  0.449
2015 Bryant RJ, Sjoberg DD, Vickers AJ, Robinson MC, Kumar R, Marsden L, Davis M, Scardino PT, Donovan J, Neal DE, Lilja H, Hamdy FC. Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study. Journal of the National Cancer Institute. 107. PMID 25863334 DOI: 10.1093/jnci/djv095  0.475
2015 Amin Al Olama A, Benlloch S, Antoniou AC, Giles GG, Severi G, Neal DE, Hamdy FC, Donovan JL, Muir K, Schleutker J, Henderson BE, Haiman CA, Schumacher FR, Pashayan N, Pharoah PD, et al. Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 24: 1121-9. PMID 25837820 DOI: 10.1158/1055-9965.Epi-14-0317  0.485
2015 Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JM, Papaemmanuil E, Brewer DS, Kallio HM, Högnäs G, Annala M, Kivinummi K, Goody V, Latimer C, O'Meara S, Dawson KJ, ... ... Neal DE, et al. The evolutionary history of lethal metastatic prostate cancer. Nature. 520: 353-7. PMID 25830880 DOI: 10.1038/Nature14347  0.46
2015 Hong MK, Macintyre G, Wedge DC, Van Loo P, Patel K, Lunke S, Alexandrov LB, Sloggett C, Cmero M, Marass F, Tsui D, Mangiola S, Lonie A, Naeem H, Sapre N, ... ... Neal D, et al. Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nature Communications. 6: 6605. PMID 25827447 DOI: 10.1038/Ncomms7605  0.404
2015 Watson E, Shinkins B, Frith E, Neal D, Hamdy F, Walter F, Weller D, Wilkinson C, Faithfull S, Wolstenholme J, Sooriakumaran P, Kastner C, Campbell C, Neal R, Butcher H, et al. Symptoms, unmet needs, psychological well-being and health status in survivors of prostate cancer: implications for redesigning follow-up. Bju International. PMID 25818406 DOI: 10.1111/bju.13122  0.406
2015 Hackshaw-McGeagh LE, Penfold CM, Walsh E, Donovan JL, Hamdy FC, Neal DE, Jeffreys M, Martin RM, Lane JA. Physical activity, alcohol consumption, BMI and smoking status before and after prostate cancer diagnosis in the ProtecT trial: opportunities for lifestyle modification. International Journal of Cancer. 137: 1509-15. PMID 25761662 DOI: 10.1002/ijc.29514  0.423
2015 Cooper CS, Eeles R, Wedge DC, Van Loo P, Gundem G, Alexandrov LB, Kremeyer B, Butler A, Lynch AG, Camacho N, Massie CE, Kay J, Luxton HJ, Edwards S, Kote-Jarai Z, ... ... Neal DE, et al. Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nature Genetics. 47: 367-72. PMID 25730763 DOI: 10.1038/Ng.3221  0.437
2015 Stegeman S, Amankwah E, Klein K, O'Mara TA, Kim D, Lin HY, Permuth-Wey J, Sellers TA, Srinivasan S, Eeles R, Easton D, Kote-Jarai Z, Amin Al Olama A, Benlloch S, Muir K, ... ... Neal D, et al. A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer. Cancer Discovery. 5: 368-79. PMID 25691096 DOI: 10.1158/2159-8290.Cd-14-1057  0.427
2015 Wong LM, Neal DE, Finelli A, Davis S, Bonner C, Kapoor J, Trachtenberg J, Thomas B, Hovens CM, Costello AJ, Corcoran NM. Evaluation of models predicting insignificant prostate cancer to select men for active surveillance of prostate cancer. Prostate Cancer and Prostatic Diseases. 18: 137-43. PMID 25667108 DOI: 10.1038/pcan.2015.1  0.478
2015 Simpkin AJ, Tilling K, Martin RM, Lane JA, Hamdy FC, Holmberg L, Neal DE, Metcalfe C, Donovan JL. Systematic Review and Meta-analysis of Factors Determining Change to Radical Treatment in Active Surveillance for Localized Prostate Cancer. European Urology. 67: 993-1005. PMID 25616709 DOI: 10.1016/j.eururo.2015.01.004  0.468
2015 Williams NJ, Hill EM, Ng SY, Martin RM, Metcalfe C, Donovan JL, Evans S, Hughes LJ, Davies CF, Hamdy FC, Neal DE, Turner EL. Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial – lessons learnt from CAP (Cluster randomised triAl of PSA testing for Prostate cancer). Bmc Medical Research Methodology. 15: 6. PMID 25613468 DOI: 10.1186/1471-2288-15-6  0.683
2015 Kote-Jarai Z, Mikropoulos C, Leongamornlert DA, Dadaev T, Tymrakiewicz M, Saunders EJ, Jones M, Jugurnauth-Little S, Govindasami K, Guy M, Hamdy FC, Donovan JL, Neal DE, Lane JA, Dearnaley D, et al. Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 26: 756-61. PMID 25595936 DOI: 10.1093/annonc/mdv004  0.463
2015 Pashayan N, Duffy SW, Neal DE, Hamdy FC, Donovan JL, Martin RM, Harrington P, Benlloch S, Amin Al Olama A, Shah M, Kote-Jarai Z, Easton DF, Eeles R, Pharoah PD. Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 17: 789-95. PMID 25569441 DOI: 10.1038/gim.2014.192  0.501
2015 Massie CE, Spiteri I, Ross-Adams H, Luxton H, Kay J, Whitaker HC, Dunning MJ, Lamb AD, Ramos-Montoya A, Brewer DS, Cooper CS, Eeles R, Warren AY, Tavaré S, ... Neal DE, et al. HES5 silencing is an early and recurrent change in prostate tumourigenesis. Endocrine-Related Cancer. 22: 131-44. PMID 25560400 DOI: 10.1530/Erc-14-0454  0.502
2015 Gilbert R, Bonilla C, Metcalfe C, Lewis S, Evans DM, Fraser WD, Kemp JP, Donovan JL, Hamdy FC, Neal DE, Lane JA, Smith GD, Lathrop M, Martin RM. Associations of vitamin D pathway genes with circulating 25-hydroxyvitamin-D, 1,25-dihydroxyvitamin-D, and prostate cancer: a nested case-control study. Cancer Causes & Control : Ccc. 26: 205-18. PMID 25488826 DOI: 10.1007/s10552-014-0500-5  0.331
2015 Oxley J, Simpkin A, Goepel J, Varma M, Griffiths D, Grigor K, Mayer N, Warren A, Deshmukh N, Bhattarai S, Dormer J, Hounsome L, Adamczyk LA, Metcalfe C, Lane JA, ... Neal DE, et al. Gleason drift in the NIHR ProtecT study. Histopathology. 66: 438-46. PMID 25231130 DOI: 10.1111/his.12549  0.424
2015 Jurmeister S, Ramos-Montoya A, Neal DE, Fryer LG. Transcriptomic analysis reveals inhibition of androgen receptor activity by AMPK in prostate cancer cells. Oncotarget. 5: 3785-99. PMID 25003216 DOI: 10.18632/ONCOTARGET.1997  0.447
2015 Volanis D, Neal DE, Warren AY, Gnanapragasam VJ. Incidence of needle-tract seeding following prostate biopsy for suspected cancer: a review of the literature. Bju International. 115: 698-704. PMID 24958224 DOI: 10.1111/bju.12849  0.421
2015 Gundem G, Loo PV, Kremeyer B, Alexandrov LB, Tubio JMC, Papaemmanuil E, Brewer DS, Kallio H, Högnäs G, Annala M, Kivinummi K, Goody V, Latimer C, O'Meara S, Dawson KJ, ... ... Neal DE, et al. Abstract 956: The evolutionary history of lethal metastatic prostate cancer Cancer Research. 75: 956-956. DOI: 10.1158/1538-7445.Am2015-956  0.474
2015 Mitchell T, Neal DE. The genomic evolution of human prostate cancer British Journal of Cancer. DOI: 10.1038/bjc.2015.234  0.452
2015 Hori S, Wadhwa K, Ramos-Montoya A, Zecchini V, Valencia T, Neal D, Gnanapragasam V. 283 Similar expression to FGF (Sef) is an important determinant of the prostate cancer cells' ability to metastasise in vivo European Urology Supplements. 14: e283. DOI: 10.1016/S1569-9056(15)60280-9  0.48
2015 Ross-Adams H, Lamb AD, Dunning MJ, Halim S, Lindberg J, Massie CM, Egevad LA, Russell R, Ramos-Montoya A, Vowler SL, Sharma NL, Kay J, Whitaker H, Clark J, Hurst R, ... ... Neal DE, et al. Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study Ebiomedicine. DOI: 10.1016/j.ebiom.2015.07.017  0.471
2015 Szulkin R, Whitington T, Eklund M, Aly M, Eeles RA, Easton D, Kote-Jarai Z, Amin Al Olama A, Benlloch S, Muir K, Giles GG, Southey MC, FitzGerald LM, Henderson BE, Schumacher F, ... ... Neal DE, et al. Prediction of individual genetic risk to prostate cancer using a polygenic score Prostate. 75: 1467-1474. DOI: 10.1002/pros.23037  0.421
2014 Mikropoulos C, Dadaev T, Tymrakiewicz M, Leongamornlert D, Saunders E, Little SJ, Govindasami K, Guy M, Wilkinson R, Morgan A, Donovan J, Neal D, Hamdy F, Antoniou A, Eeles R, et al. 751OPREVALENCE OF HOXB13G84E GERMLINE MUTATION IN UK PROSTATE CANCER CASES; CORRELATION WITH TUMOUR CHARACTERISTICS AND OUTCOMES. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv254. PMID 28171449 DOI: 10.1093/annonc/mdu335.2  0.408
2014 Lalonde E, Ishkanian AS, Sykes J, Fraser M, Ross-Adams H, Erho N, Dunning MJ, Halim S, Lamb AD, Moon NC, Zafarana G, Warren AY, Meng X, Thoms J, Grzadkowski MR, ... ... Neal DE, et al. Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. The Lancet. Oncology. 15: 1521-32. PMID 25456371 DOI: 10.1016/S1470-2045(14)71021-6  0.501
2014 Horwood JP, Avery KN, Metcalfe C, Donovan JL, Hamdy FC, Neal DE, Lane JA. Men's knowledge and attitudes towards dietary prevention of a prostate cancer diagnosis: a qualitative study. Bmc Cancer. 14: 812. PMID 25374269 DOI: 10.1186/1471-2407-14-812  0.487
2014 Weng PH, Huang YL, Page JH, Chen JH, Xu J, Koutros S, Berndt S, Chanock S, Yeager M, Witte JS, Eeles RA, Easton DF, Neal DE, Donovan J, Hamdy FC, et al. Polymorphisms of an innate immune gene, toll-like receptor 4, and aggressive prostate cancer risk: a systematic review and meta-analysis. Plos One. 9: e110569. PMID 25360682 DOI: 10.1371/Journal.Pone.0110569  0.338
2014 Al Olama AA, Kote-Jarai Z, Berndt SI, Conti DV, Schumacher F, Han Y, Benlloch S, Hazelett DJ, Wang Z, Saunders E, Leongamornlert D, Lindstrom S, Jugurnauth-Little S, Dadaev T, Tymrakiewicz M, ... Neal DE, et al. A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nature Genetics. 46: 1103-9. PMID 25217961 DOI: 10.1038/Ng.3094  0.489
2014 Lane JA, Donovan JL, Davis M, Walsh E, Dedman D, Down L, Turner EL, Mason MD, Metcalfe C, Peters TJ, Martin RM, Neal DE, Hamdy FC. Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. The Lancet. Oncology. 15: 1109-18. PMID 25163905 DOI: 10.1016/S1470-2045(14)70361-4  0.51
2014 Er V, Lane JA, Martin RM, Emmett P, Gilbert R, Avery KN, Walsh E, Donovan JL, Neal DE, Hamdy FC, Jeffreys M. Adherence to dietary and lifestyle recommendations and prostate cancer risk in the prostate testing for cancer and treatment (ProtecT) trial. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 23: 2066-77. PMID 25017249 DOI: 10.1158/1055-9965.EPI-14-0322  0.532
2014 Avery KN, Donovan JL, Horwood J, Neal DE, Hamdy FC, Parker C, Wade J, Lane A. The importance of dietary change for men diagnosed with and at risk of prostate cancer: a multi-centre interview study with men, their partners and health professionals. Bmc Family Practice. 15: 81. PMID 24886169 DOI: 10.1186/1471-2296-15-81  0.353
2014 Turner EL, Metcalfe C, Donovan JL, Noble S, Sterne JA, Lane JA, Avery KN, Down L, Walsh E, Davis M, Ben-Shlomo Y, Oliver SE, Evans S, Brindle P, Williams NJ, ... ... Neal DE, et al. Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP). British Journal of Cancer. 110: 2829-36. PMID 24867688 DOI: 10.1038/bjc.2014.242  0.476
2014 Watson E, Rose P, Frith E, Hamdy F, Neal D, Kastner C, Russell S, Walter FM, Faithfull S, Wolstenholme J, Perera R, Weller D, Campbell C, Wilkinson C, Neal R, et al. PROSPECTIV-a pilot trial of a nurse-led psychoeducational intervention delivered in primary care to prostate cancer survivors: study protocol for a randomised controlled trial. Bmj Open. 4: e005186. PMID 24852301 DOI: 10.1136/bmjopen-2014-005186  0.397
2014 Zecchini V, Madhu B, Russell R, Pértega-Gomes N, Warren A, Gaude E, Borlido J, Stark R, Ireland-Zecchini H, Rao R, Scott H, Boren J, Massie C, Asim M, Brindle K, ... Neal DE, et al. Nuclear ARRB1 induces pseudohypoxia and cellular metabolism reprogramming in prostate cancer. The Embo Journal. 33: 1365-82. PMID 24837709 DOI: 10.15252/Embj.201386874  0.384
2014 Xiong T, Turner RM, Wei Y, Neal DE, Lyratzopoulos G, Higgins JP. Comparative efficacy and safety of treatments for localised prostate cancer: an application of network meta-analysis. Bmj Open. 4: e004285. PMID 24833678 DOI: 10.1136/bmjopen-2013-004285  0.463
2014 Knipe DW, Evans DM, Kemp JP, Eeles R, Easton DF, Kote-Jarai Z, Al Olama AA, Benlloch S, Donovan JL, Hamdy FC, Neal DE, Davey Smith G, Lathrop M, Martin RM. Genetic variation in prostate-specific antigen-detected prostate cancer and the effect of control selection on genetic association studies. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 23: 1356-65. PMID 24753544 DOI: 10.1158/1055-9965.EPI-13-0889  0.485
2014 Sharma NL, Massie CE, Butter F, Mann M, Bon H, Ramos-Montoya A, Menon S, Stark R, Lamb AD, Scott HE, Warren AY, Neal DE, Mills IG. The ETS family member GABPα modulates androgen receptor signalling and mediates an aggressive phenotype in prostate cancer. Nucleic Acids Research. 42: 6256-69. PMID 24753418 DOI: 10.1093/Nar/Gku281  0.377
2014 Ramos-Montoya A, Lamb AD, Russell R, Carroll T, Jurmeister S, Galeano-Dalmau N, Massie CE, Boren J, Bon H, Theodorou V, Vias M, Shaw GL, Sharma NL, Ross-Adams H, Scott HE, ... Neal DE, et al. HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network. Embo Molecular Medicine. 6: 651-61. PMID 24737870 DOI: 10.1002/emmm.201303581  0.441
2014 Shaw GL, Thomas BC, Dawson SN, Srivastava G, Vowler SL, Gnanapragasam VJ, Shah NC, Warren AY, Neal DE. Identification of pathologically insignificant prostate cancer is not accurate in unscreened men. British Journal of Cancer. 110: 2405-11. PMID 24722183 DOI: 10.1038/bjc.2014.192  0.486
2014 Elliker KR, Sommerville BA, Broom DM, Neal DE, Armstrong S, Williams HC. Key considerations for the experimental training and evaluation of cancer odour detection dogs: lessons learnt from a double-blind, controlled trial of prostate cancer detection. Bmc Urology. 14: 22. PMID 24575737 DOI: 10.1186/1471-2490-14-22  0.423
2014 Nelson AW, Tilley WD, Neal DE, Carroll JS. Estrogen receptor beta in prostate cancer: friend or foe? Endocrine-Related Cancer. 21: T219-34. PMID 24402043 DOI: 10.1530/ERC-13-0508  0.512
2014 Robinson JL, Hickey TE, Warren AY, Vowler SL, Carroll T, Lamb AD, Papoutsoglou N, Neal DE, Tilley WD, Carroll JS. Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype. Oncogene. 33: 5666-74. PMID 24292680 DOI: 10.1038/onc.2013.508  0.481
2014 Sooriakumaran P, Srivastava A, Shariat SF, Stricker PD, Ahlering T, Eden CG, Wiklund PN, Sanchez-Salas R, Mottrie A, Lee D, Neal DE, Ghavamian R, Nyirady P, Nilsson A, Carlsson S, et al. A multinational, multi-institutional study comparing positive surgical margin rates among 22393 open, laparoscopic, and robot-assisted radical prostatectomy patients. European Urology. 66: 450-6. PMID 24290695 DOI: 10.1016/j.eururo.2013.11.018  0.304
2014 Whitaker HC, Shiong LL, Kay JD, Grönberg H, Warren AY, Seipel A, Wiklund F, Thomas B, Wiklund P, Miller JL, Menon S, Ramos-Montoya A, Vowler SL, Massie C, Egevad L, ... Neal DE, et al. N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 is overexpressed in cancer and promotes a pro-migratory and pro-metastatic phenotype. Oncogene. 33: 5274-87. PMID 24240687 DOI: 10.1038/onc.2013.464  0.393
2014 Aggarwal A, Cathcart P, Payne H, Neal D, Rashbass J, Nossiter J, van der Meulen J. The National Prostate Cancer Audit - introducing a new generation of cancer audit. Clinical Oncology (Royal College of Radiologists (Great Britain)). 26: 90-3. PMID 24211033 DOI: 10.1016/j.clon.2013.10.006  0.502
2014 Lamb AD, Massie CE, Neal DE. The transcriptional programme of the androgen receptor (AR) in prostate cancer. Bju International. 113: 358-66. PMID 24053777 DOI: 10.1111/bju.12415  0.436
2014 Ankerst DP, Boeck A, Freedland SJ, Jones JS, Cronin AM, Roobol MJ, Hugosson J, Kattan MW, Klein EA, Hamdy F, Neal D, Donovan J, Parekh DJ, Klocker H, Horninger W, et al. Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World Journal of Urology. 32: 185-91. PMID 22527674 DOI: 10.1007/S00345-012-0869-2  0.519
2014 Lamb A, Ramos-Montoya A, Russell R, Carroll T, Massie C, Shaw G, Sharma N, Warren A, Wooster R, Mills I, Neal D. 836 Hes6 drives a critical androgen receptor (AR) transcriptional program to induce castration resistant prostate cancer (CRPC) through activation of an E2F1-mediated cell cycle network European Urology Supplements. 13: e836. DOI: 10.1016/S1569-9056(14)60823-X  0.369
2014 Bonilla C, Rowlands M, Lewis S, Palmer T, Gaunt T, Davey Smith G, Gunnell D, Donovan J, Hamdy F, Neal D, Lathrop M, Martin R, Holly J. OR4-4: The causal role of IGFs and IGFBPs in prostate cancer: a Mendelian randomization study Growth Hormone & Igf Research. 24: S13. DOI: 10.1016/S1096-6374(14)50032-9  0.511
2014 Lamb AD, Ramos-Montoya A, Russell R, Carroll T, Massie CE, Shaw GL, Sharma NL, Warren AY, Mills IG, Neal DE. Role of Hes6 in castration-resistant prostate cancer The Lancet. 383: S67. DOI: 10.1016/S0140-6736(14)60330-5  0.472
2013 Simpkin AJ, Metcalfe C, Martin RM, Lane JA, Donovan JL, Hamdy FC, Neal DE, Tilling K. Longitudinal prostate-specific antigen reference ranges: Choosing the underlying model of age-related changes. Statistical Methods in Medical Research. PMID 24108270 DOI: 10.1177/0962280213503928  0.396
2013 Cathcart P, Nossiter J, Aggarwal A, Rashbass J, Lyratzopoulos Y, Payne H, Neal DE, van der Meulen J. The first national clinical audit of prostate cancer care. Bju International. 112: 883-4. PMID 24053511 DOI: 10.1111/bju.12365  0.459
2013 Whitaker HC, Patel D, Howat WJ, Warren AY, Kay JD, Sangan T, Marioni JC, Mitchell J, Aldridge S, Luxton HJ, Massie C, Lynch AG, Neal DE. Peroxiredoxin-3 is overexpressed in prostate cancer and promotes cancer cell survival by protecting cells from oxidative stress. British Journal of Cancer. 109: 983-93. PMID 23880827 DOI: 10.1038/bjc.2013.396  0.432
2013 Zecchini V, Neal DE. Targeting the pro-survival side-effects of androgen-deprivation therapy in prostate cancer. Bju International. 111: 532-3. PMID 23551440 DOI: 10.1111/j.1464-410X.2013.11452.x  0.45
2013 Kote-Jarai Z, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Dadaev T, Jugurnauth-Little S, Ross-Adams H, Al Olama AA, Benlloch S, Halim S, Russell R, Russel R, Dunning AM, Luccarini C, Dennis J, Neal DE, et al. Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. Human Molecular Genetics. 22: 2520-8. PMID 23535824 DOI: 10.1093/Hmg/Ddt086  0.33
2013 Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Ghoussaini M, Luccarini C, Dennis J, Jugurnauth-Little S, Dadaev T, Neal DE, Hamdy FC, Donovan JL, Muir K, et al. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nature Genetics. 45: 385-91, 391e1-2. PMID 23535732 DOI: 10.1038/Ng.2560  0.487
2013 Avery KN, Donovan JL, Gilbert R, Davis M, Emmett P, Down L, Oliver S, Neal DE, Hamdy FC, Lane JA. Men with prostate cancer make positive dietary changes following diagnosis and treatment. Cancer Causes & Control : Ccc. 24: 1119-28. PMID 23519639 DOI: 10.1007/s10552-013-0189-x  0.479
2013 Johnston R, Wong LM, Warren A, Shah N, Neal D. The role of 1.5 Tesla magnetic resonance imaging in staging prostate cancer. Anz Journal of Surgery. 83: 234-8. PMID 23463964 DOI: 10.1111/ans.12094  0.344
2013 Bonilla C, Gilbert R, Kemp JP, Timpson NJ, Evans DM, Donovan JL, Hamdy FC, Neal DE, Fraser WD, Davey SG, Lewis SJ, Lathrop M, Martin RM. Using genetic proxies for lifecourse sun exposure to assess the causal relationship of sun exposure with circulating vitamin d and prostate cancer risk. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 22: 597-606. PMID 23441100 DOI: 10.1158/1055-9965.EPI-12-1248  0.404
2013 Mitchell T, Ramos-Montoya A, Di Antonio M, Murat P, Ohnmacht S, Micco M, Jurmeister S, Fryer L, Balasubramanian S, Neidle S, Neal DE. Downregulation of androgen receptor transcription by promoter g-quadruplex stabilization as a potential alternative treatment for castrate-resistant prostate cancer. Biochemistry. 52: 1429-36. PMID 23363071 DOI: 10.1021/Bi301349C  0.333
2013 Thomas BC, Neal DE. Androgen deprivation treatment in prostate cancer. Bmj (Clinical Research Ed.). 346: e8555. PMID 23303885 DOI: 10.1136/bmj.e8555  0.51
2013 Sharma NL, Massie CE, Ramos-Montoya A, Zecchini V, Scott HE, Lamb AD, MacArthur S, Stark R, Warren AY, Mills IG, Neal DE. The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. Cancer Cell. 23: 35-47. PMID 23260764 DOI: 10.1016/j.ccr.2012.11.010  0.467
2013 Burton A, Martin RM, Holly J, Lane JA, Donovan JL, Hamdy FC, Neal DE, Tilling K. Associations of adiponectin and leptin with stage and grade of PSA-detected prostate cancer: the ProtecT study. Cancer Causes & Control : Ccc. 24: 323-34. PMID 23224325 DOI: 10.1007/s10552-012-0118-4  0.48
2013 Rodriguez S, Al-Ghamdi OA, Burrows K, Guthrie PA, Lane JA, Davis M, Marsden G, Alharbi KK, Cox A, Hamdy FC, Neal DE, Donovan JL, Day IN. Very low PSA concentrations and deletions of the KLK3 gene. Clinical Chemistry. 59: 234-44. PMID 23169475 DOI: 10.1373/clinchem.2012.192815  0.359
2013 Rowlands MA, Tilling K, Holly JM, Metcalfe C, Gunnell D, Lane A, Davis M, Donovan J, Hamdy F, Neal DE, Martin RM. Insulin-like growth factors (IGFs) and IGF-binding proteins in active monitoring of localized prostate cancer: a population-based observational study. Cancer Causes & Control : Ccc. 24: 39-45. PMID 23085814 DOI: 10.1007/s10552-012-0087-7  0.338
2013 Zuccolo L, Lewis SJ, Donovan JL, Hamdy FC, Neal DE, Smith GD. Alcohol consumption and PSA-detected prostate cancer risk--a case-control nested in the ProtecT study. International Journal of Cancer. Journal International Du Cancer. 132: 2176-85. PMID 23024014 DOI: 10.1002/ijc.27877  0.444
2013 Orozco G, Goh CL, Al Olama AA, Benlloch-Garcia S, Govindasami K, Guy M, Muir KR, Giles GG, Severi G, Neal DE, Hamdy FC, Donovan JL, Kote-Jarai Z, Easton DF, Eyre S, et al. Common genetic variants associated with disease from genome-wide association studies are mutually exclusive in prostate cancer and rheumatoid arthritis. Bju International. 111: 1148-55. PMID 22985493 DOI: 10.1111/j.1464-410X.2012.11492.x  0.385
2013 Gilbert R, Metcalfe C, Fraser WD, Lewis S, Donovan J, Hamdy F, Neal DE, Lane JA, Martin RM, Tilling K. Associations of circulating 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and vitamin D pathway genes with prostate-specific antigen progression in men with localized prostate cancer undergoing active monitoring. European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (Ecp). 22: 121-5. PMID 22955340 DOI: 10.1097/CEJ.0b013e3283584954  0.348
2013 Lose F, Batra J, O'Mara T, Fahey P, Marquart L, Eeles RA, Easton DF, Al Olama AA, Kote-Jarai Z, Guy M, Muir K, Lophatananon A, Rahman AA, Neal DE, Hamdy FC, et al. Common variation in Kallikrein genes KLK5, KLK6, KLK12, and KLK13 and risk of prostate cancer and tumor aggressiveness. Urologic Oncology. 31: 635-43. PMID 21741862 DOI: 10.1016/j.urolonc.2011.05.011  0.501
2013 Castro E, Bancroft E, Taylor N, Dadaev T, Page E, Keating D, Borley N, DeSouza N, Saunders E, Lee A, Neal D, Antoniou AC, Kote-Jarai Z, Eeles RA. Profile study: Genetic prostate cancer risk stratification for targeted screening. Journal of Clinical Oncology. 31: 5054-5054. DOI: 10.1200/JCO.2013.31.15_SUPPL.5054  0.349
2013 asim M, Massie C, Zecchini H, Baridi A, Gomes N, Mohammed H, Zecchini V, Madhu B, Qureshi A, Russell R, Hessenkemper W, Sriranjan R, Yang C, Lynch A, Gregorengko E, ... ... Neal D, et al. Abstract B133: Regulation of the androgen receptor function by a metabolic kinase in prostate cancer. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B133  0.451
2013 Tran M, Lo F, Ramos-Montoya A, Scott H, Menon S, Carroll T, Osborne M, Hadfield J, Cheung S, Warren A, Shukla D, Massie C, Maxwell P, Mills I, Neal D. 935 Activation of HIF1α promotes androgen independent prostate cancer cell growth European Urology Supplements. 12: e935. DOI: 10.1016/S1569-9056(13)61414-1  0.473
2013 Mitchell T, Ramos-Montoya A, Di Antonio M, Murat P, Ohnmacht S, Micco M, Fryer L, Balasubramanian S, Neidle S, Neal D. 823 Transcriptional down-regulation of the androgen receptor by promoter G-quadruplex stabilisation; a potential alternative treatment in castrate-resistant prostate cancer European Urology Supplements. 12: e823-e824. DOI: 10.1016/S1569-9056(13)61303-2  0.394
2013 Shaw G, Thomas B, Sarah D, Vowler S, Gnanapragasam V, Shah N, Neal D. 551 D'AMICO RISK STRATIFICATION OUTPERFORMS PUBLISHED ACTIVE SURVEILLANCE SELECTION CRITERIA FROM THE USA AS A WAY TO IDENTIFY PATIENTS WITH INDOLENT PROSTATE CANCER IN A RELATIVELY UNSCREENED UK POPULATION Journal of Urology. 189. DOI: 10.1016/J.JURO.2013.02.1947  0.409
2013 Shaw GL, Neal DE. Molecular biology and prostate cancer Prostate Cancer: a Comprehensive Perspective. 19-34. DOI: 10.1007/978-1-4471-2864-9_2  0.51
2013 Kirby R, Eeles R, Neal D, Ahmed HU, Dearnaley D. Prostate Cancer UK: the Blue Skies Forum Trends in Urology & Men's Health. 4: 39-43. DOI: 10.1002/TRE.369  0.533
2013 Lamb AD, Neal DE. Role of the androgen receptor in prostate cancer Trends in Urology & Men's Health. 4: 26-30. DOI: 10.1002/TRE.331  0.494
2012 Ramsay C, Pickard R, Robertson C, Close A, Vale L, Armstrong N, Barocas DA, Eden CG, Fraser C, Gurung T, Jenkinson D, Jia X, Lam TB, Mowatt G, Neal DE, et al. Systematic review and economic modelling of the relative clinical benefit and cost-effectiveness of laparoscopic surgery and robotic surgery for removal of the prostate in men with localised prostate cancer. Health Technology Assessment (Winchester, England). 16: 1-313. PMID 23127367 DOI: 10.3310/hta16410  0.397
2012 Gudmundsson J, Sulem P, Gudbjartsson DF, Masson G, Agnarsson BA, Benediktsdottir KR, Sigurdsson A, Magnusson OT, Gudjonsson SA, Magnusdottir DN, Johannsdottir H, Helgadottir HT, Stacey SN, Jonasdottir A, Olafsdottir SB, ... Neal DE, et al. A study based on whole-genome sequencing yields a rare variant at 8q24 associated with prostate cancer. Nature Genetics. 44: 1326-9. PMID 23104005 DOI: 10.1038/Ng.2437  0.459
2012 Wong LM, Neal DE, Johnston RB, Shah N, Sharma N, Warren AY, Hovens CM, Larry Goldenberg S, Gleave ME, Costello AJ, Corcoran NM. International multicentre study examining selection criteria for active surveillance in men undergoing radical prostatectomy. British Journal of Cancer. 107: 1467-73. PMID 23037714 DOI: 10.1038/bjc.2012.400  0.409
2012 Cheng I, Chen GK, Nakagawa H, He J, Wan P, Laurie CC, Shen J, Sheng X, Pooler LC, Crenshaw AT, Mirel DB, Takahashi A, Kubo M, Nakamura Y, Al Olama AA, ... Neal DE, et al. Evaluating genetic risk for prostate cancer among Japanese and Latinos. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 21: 2048-58. PMID 22923026 DOI: 10.1158/1055-9965.Epi-12-0598  0.473
2012 Burton AJ, Martin RM, Donovan JL, Lane JA, Davis M, Hamdy FC, Neal DE, Tilling K. Associations of lifestyle factors and anthropometric measures with repeat PSA levels during active surveillance/monitoring. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 21: 1877-85. PMID 22859401 DOI: 10.1158/1055-9965.EPI-12-0411  0.408
2012 Grisanzio C, Werner L, Takeda D, Awoyemi BC, Pomerantz MM, Yamada H, Sooriakumaran P, Robinson BD, Leung R, Schinzel AC, Mills I, Ross-Adams H, Neal DE, Kido M, Yamamoto T, et al. Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis. Proceedings of the National Academy of Sciences of the United States of America. 109: 11252-7. PMID 22730461 DOI: 10.1073/Pnas.1200853109  0.38
2012 Groom HC, Warren AY, Neal DE, Bishop KN. No evidence for infection of UK prostate cancer patients with XMRV, BK virus, Trichomonas vaginalis or human papilloma viruses. Plos One. 7: e34221. PMID 22470540 DOI: 10.1371/journal.pone.0034221  0.365
2012 Gilbert R, Martin RM, Fraser WD, Lewis S, Donovan J, Hamdy F, Neal DE, Lane JA, Metcalfe C. Predictors of 25-hydroxyvitamin D and its association with risk factors for prostate cancer: evidence from the prostate testing for cancer and treatment study. Cancer Causes & Control : Ccc. 23: 575-88. PMID 22382867 DOI: 10.1007/s10552-012-9919-8  0.314
2012 Avery KN, Metcalfe C, Vedhara K, Lane JA, Davis M, Neal DE, Hamdy FC, Donovan JL, Blazeby JM. Predictors of attendance for prostate-specific antigen screening tests and prostate biopsy. European Urology. 62: 649-55. PMID 22244151 DOI: 10.1016/j.eururo.2011.12.059  0.467
2012 Rosario DJ, Lane JA, Metcalfe C, Donovan JL, Doble A, Goodwin L, Davis M, Catto JW, Avery K, Neal DE, Hamdy FC. Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. Bmj (Clinical Research Ed.). 344: d7894. PMID 22232535 DOI: 10.1136/bmj.d7894  0.437
2012 Ankerst DP, Boeck A, Freedland SJ, Thompson IM, Cronin AM, Roobol MJ, Hugosson J, Stephen Jones J, Kattan MW, Klein EA, Hamdy F, Neal D, Donovan J, Parekh DJ, Klocker H, et al. Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World Journal of Urology. 30: 181-7. PMID 22210512 DOI: 10.1007/S00345-011-0818-5  0.497
2012 Roobol MJ, Schröder FH, Hugosson J, Jones JS, Kattan MW, Klein EA, Hamdy F, Neal D, Donovan J, Parekh DJ, Ankerst D, Bartsch G, Klocker H, Horninger W, Benchikh A, et al. Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group. World Journal of Urology. 30: 149-55. PMID 22203238 DOI: 10.1007/S00345-011-0804-Y  0.503
2012 Rowlands MA, Holly JM, Hamdy F, Phillips J, Goodwin L, Marsden G, Gunnell D, Donovan J, Neal DE, Martin RM. Serum insulin-like growth factors and mortality in localised and advanced clinically detected prostate cancer. Cancer Causes & Control : Ccc. 23: 347-54. PMID 22183619 DOI: 10.1007/s10552-011-9883-8  0.454
2012 Barrett T, Gill AB, Kataoka MY, Priest AN, Joubert I, McLean MA, Graves MJ, Stearn S, Lomas DJ, Griffiths JR, Neal D, Gnanapragasam VJ, Sala E. DCE and DW MRI in monitoring response to androgen deprivation therapy in patients with prostate cancer: a feasibility study. Magnetic Resonance in Medicine. 67: 778-85. PMID 22135228 DOI: 10.1002/mrm.23062  0.337
2012 Rowlands MA, Holly JM, Gunnell D, Donovan J, Lane JA, Hamdy F, Neal DE, Oliver S, Smith GD, Martin RM. Circulating insulin-like growth factors and IGF-binding proteins in PSA-detected prostate cancer: the large case-control study ProtecT. Cancer Research. 72: 503-15. PMID 22106399 DOI: 10.1158/0008-5472.CAN-11-1601  0.462
2012 Wong LM, Johnston R, Sharma N, Shah NC, Warren AY, Neal DE. General application of the National Institute for Health and Clinical Excellence (NICE) guidance for active surveillance for men with prostate cancer is not appropriate in unscreened populations. Bju International. 110: 24-7. PMID 22077729 DOI: 10.1111/j.1464-410X.2011.10730.x  0.503
2012 Gilbert R, Metcalfe C, Fraser WD, Donovan J, Hamdy F, Neal DE, Lane JA, Martin RM. Associations of circulating 25-hydroxyvitamin D with prostate cancer diagnosis, stage and grade. International Journal of Cancer. 131: 1187-96. PMID 22033893 DOI: 10.1002/ijc.27327  0.452
2012 Gnanapragasam VJ, Mason MD, Shaw GL, Neal DE. The role of surgery in high-risk localised prostate cancer. Bju International. 109: 648-58. PMID 21951841 DOI: 10.1111/j.1464-410X.2011.10596.x  0.376
2012 Barbiere JM, Greenberg DC, Wright KA, Brown CH, Palmer C, Neal DE, Lyratzopoulos G. The association of diagnosis in the private or NHS sector on prostate cancer stage and treatment. Journal of Public Health (Oxford, England). 34: 108-14. PMID 21745831 DOI: 10.1093/pubmed/fdr051  0.467
2012 Kocurek JN, Orihuela E, Neal DE, Pow-Sang M, Warren MM. Are we overlooking stage a prostate cancer in patients treated for benign prostatic hyperplasia with medical or minimally invasive modalities? Urologic Oncology. 1: 153-5. PMID 21224109 DOI: 10.1016/1078-1439(95)00060-7  0.451
2012 McDunn J, Whitaker H, Li Z, Adam K, Milburn M, Neri B, Neal D. Abstract 4541: Metabolomic diagnosis of prostate cancer from urine Cancer Research. 72: 4541-4541. DOI: 10.1158/1538-7445.Am2012-4541  0.509
2012 Wong L, Johnston R, Neal D, Warren A, Shah N, Hovens C, Goldenberg S, Gleave M, Costello A, Corcoran N. 1093 An international multi-center study examining re-classification rates of patients with prostate cancer suitable active surveillance whom underwent radical prostatectomy European Urology Supplements. 11: e1093-e1093a. DOI: 10.1016/S1569-9056(12)61089-6  0.451
2012 Sharma N, Massie C, Ramos-Montoya A, Scott H, Stark R, Warren A, Mills I, Neal D. 942 The androgen receptor induces a distinct transcriptional program in castration resistant prostate cancer in man European Urology Supplements. 11: e942-e942a. DOI: 10.1016/S1569-9056(12)60939-7  0.416
2012 Sooriakumaran P, Heus I, Shariat S, Srivastava A, Rink M, Sanchez-Salas R, Chun F, Chromecki T, Nyberg T, Nilsson A, Carlsson S, Nyirady P, Novara G, Slawin K, Cathelineau X, ... ... Neal D, et al. 876 Comparative analyses of surgical modalities for the management of prostate cancer: A multi-institutional study of positive surgical margin rates on 22,403 patients operated on in the new millennium European Urology Supplements. 11: e876-e876b. DOI: 10.1016/S1569-9056(12)60873-2  0.361
2011 Collin SM, Metcalfe C, Palmer TM, Refsum H, Lewis SJ, Smith GD, Cox A, Davis M, Marsden G, Johnston C, Lane JA, Donovan JL, Neal DE, Hamdy FC, Smith AD, et al. The causal roles of vitamin B(12) and transcobalamin in prostate cancer: can Mendelian randomization analysis provide definitive answers? International Journal of Molecular Epidemiology and Genetics. 2: 316-27. PMID 22199995  0.402
2011 Batra J, Lose F, O'Mara T, Marquart L, Stephens C, Alexander K, Srinivasan S, Eeles RA, Easton DF, Al Olama AA, Kote-Jarai Z, Guy M, Muir K, Lophatananon A, Rahman AA, Neal DE, et al. Association between Prostinogen (KLK15) genetic variants and prostate cancer risk and aggressiveness in Australia and a meta-analysis of GWAS data. Plos One. 6: e26527. PMID 22132073 DOI: 10.1371/journal.pone.0026527  0.518
2011 Catto JW, Robinson MC, Albertsen PC, Goepel JR, Abbod MF, Linkens DA, Davis M, Rosario DJ, Warren AY, Varma M, Griffiths DF, Grigor KM, Mayer NJ, Oxley JD, Deshmukh NS, ... ... Neal DE, et al. Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study. British Journal of Cancer. 105: 931-7. PMID 21863028 DOI: 10.1038/bjc.2011.314  0.473
2011 Kote-Jarai Z, Olama AA, Giles GG, Severi G, Schleutker J, Weischer M, Campa D, Riboli E, Key T, Gronberg H, Hunter DJ, Kraft P, Thun MJ, Ingles S, Chanock S, ... Neal DE, et al. Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nature Genetics. 43: 785-91. PMID 21743467 DOI: 10.1038/Ng.882  0.43
2011 Massie CE, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L, Warren A, Scott H, Madhu B, Sharma N, Bon H, Zecchini V, Smith DM, Denicola GM, Mathews N, ... Neal DE, et al. The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. The Embo Journal. 30: 2719-33. PMID 21602788 DOI: 10.1038/Emboj.2011.158  0.445
2011 Madden T, Doble A, Aliyu SH, Neal DE. Infective complications after transrectal ultrasound-guided prostate biopsy following a new protocol for antibiotic prophylaxis aimed at reducing hospital-acquired infections. Bju International. 108: 1597-602. PMID 21592292 DOI: 10.1111/j.1464-410X.2011.10160.x  0.301
2011 Williams N, Hughes LJ, Turner EL, Donovan JL, Hamdy FC, Neal DE, Martin RM, Metcalfe C. Prostate-specific antigen testing rates remain low in UK general practice: a cross-sectional study in six English cities. Bju International. 108: 1402-8. PMID 21481132 DOI: 10.1111/j.1464-410X.2011.10163.x  0.377
2011 Pashayan N, Duffy SW, Chowdhury S, Dent T, Burton H, Neal DE, Easton DF, Eeles R, Pharoah P. Polygenic susceptibility to prostate and breast cancer: implications for personalised screening. British Journal of Cancer. 104: 1656-63. PMID 21468051 DOI: 10.1038/bjc.2011.118  0.396
2011 Down L, Metcalfe C, Martin RM, Neal DE, Hamdy FC, Donovan JL, Lane JA. Seasonal variation in prostate-specific antigen levels: a large cross-sectional study of men in the UK. Bju International. 108: 1409-14. PMID 21453347 DOI: 10.1111/j.1464-410X.2011.10174.x  0.39
2011 McLean MA, Barrett T, Gnanapragasam VJ, Priest AN, Joubert I, Lomas DJ, Neal DE, Griffiths JR, Sala E. Prostate cancer metabolite quantification relative to water in 1H-MRSI in vivo at 3 Tesla. Magnetic Resonance in Medicine. 65: 914-9. PMID 21413057 DOI: 10.1002/mrm.22703  0.317
2011 Morgan R, Boxall A, Bhatt A, Bailey M, Hindley R, Langley S, Whitaker HC, Neal DE, Ismail M, Whitaker H, Annels N, Michael A, Pandha H. Engrailed-2 (EN2): a tumor specific urinary biomarker for the early diagnosis of prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 1090-8. PMID 21364037 DOI: 10.1158/1078-0432.CCR-10-2410  0.503
2011 Dimitropoulou P, Martin RM, Turner EL, Lane JA, Gilbert R, Davis M, Donovan JL, Hamdy FC, Neal DE. Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study. British Journal of Cancer. 104: 875-81. PMID 21266978 DOI: 10.1038/sj.bjc.6606066  0.464
2011 Whitaker HC, Neal DE. RAS pathways in prostate cancer - mediators of hormone resistance? Current Cancer Drug Targets. 10: 834-9. PMID 20718703 DOI: 10.2174/156800910793358005  0.431
2011 Murad AS, Down L, Davey Smith G, Donovan JL, Athene Lane J, Hamdy FC, Neal DE, Martin RM. Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, population-based, case-control study (the ProtecT study). International Journal of Cancer. Journal International Du Cancer. 128: 1442-8. PMID 20506261 DOI: 10.1002/ijc.25465  0.486
2011 Pashayan N, Pharoah P, Neal DE, Hamdy F, Donovan J, Martin RM, Greenberg D, Duffy SW. PSA-detected prostate cancer and the potential for dedifferentiation--estimating the proportion capable of progression. International Journal of Cancer. Journal International Du Cancer. 128: 1462-70. PMID 20499312 DOI: 10.1002/Ijc.25471  0.498
2011 Turner EL, Lane JA, Donovan JL, Davis MJ, Metcalfe C, Neal DE, Hamdy FC, Martin RM. Association of diabetes mellitus with prostate cancer: nested case-control study (Prostate testing for cancer and treatment study). International Journal of Cancer. Journal International Du Cancer. 128: 440-6. PMID 20473853 DOI: 10.1002/ijc.25360  0.462
2011 Girling JS, Whitaker HC, Mills IG, Neal DE. Pathogenesis of prostate cancer and hormone refractory prostate cancer. Indian Journal of Urology : Iju : Journal of the Urological Society of India. 23: 35-42. PMID 19675761 DOI: 10.4103/0970-1591.30265  0.524
2011 Burton A, Martin R, Holly J, Hamdy F, Neal D, Donovan J, Tilling K. P2-34 Association of anthropometric and lifestyle factors with prostate specific antigen (PSA) trajectories in men with localised prostate cancer undergoing active monitoring Journal of Epidemiology & Community Health. 65: A229-A229. DOI: 10.1136/jech.2011.142976h.70  0.486
2011 Zuccolo L, Lewis S, Hamdy F, Neal D, Donovan J, Smith GD. O6-2.5 Alcohol and prostate cancer risk: a mendelian randomisation approach Journal of Epidemiology & Community Health. 65: A60-A60. DOI: 10.1136/jech.2011.142976b.75  0.374
2011 Burton A, Martin R, Holly J, Hamdy F, Neal D, Donovan J, Tilling K. 743 ASSOCIATION OF ANTHROPOMETRIC AND LIFESTYLE FACTORS WITH PROSTATE SPECIFIC ANTIGEN (PSA) TRAJECTORIES IN MEN WITH LOCALISED PROSTATE CANCER UNDERGOING ACTIVE MONITORING European Urology Supplements. 10: 237. DOI: 10.1016/S1569-9056(11)60731-8  0.491
2011 Rowlands M, Holly J, Gunnell D, Donovan J, Lane J, Hamdy F, Neal D, Oliver S, Davey Smith G, Martin R. 643 INSULIN-LIKE GROWTH FACTORS (IGFS) AND IGF BINDING PROTEINS IN PSA-DETECTED PROSTATE CANCER: A LARGE POPULATION-BASED CASE CONTROL STUDY (PROTECT) European Urology Supplements. 10: 208. DOI: 10.1016/S1569-9056(11)60632-5  0.329
2011 Gudmundsson J, Gulcher J, Besenbacher S, Sulem P, Gudbjartsson D, Olafsson I, Arinbjarnarson S, Agnarsson B, Benediktsdottir K, Isaksson H, Bjornsdottir U, Eyjolfsson G, Donovan J, Hamdy F, Catalona W, ... ... Neal D, et al. 992 GENETIC CORRECTION OF PSA LEVELS AND PROSTATE CANCER RISK MARKERS IMPROVE POSITIVE PREDICTIVE VALUE OF THE PSA TEST Journal of Urology. 185. DOI: 10.1016/j.juro.2011.02.1024  0.426
2010 Murad AS, Smith GD, Lewis SJ, Cox A, Donovan JL, Neal DE, Hamdy FC, Martin RM. A polymorphism in the glucokinase gene that raises plasma fasting glucose, rs1799884, is associated with diabetes mellitus and prostate cancer: findings from a population-based, case-control study (the ProtecT study). International Journal of Molecular Epidemiology and Genetics. 1: 175-83. PMID 21537389  0.424
2010 Gudmundsson J, Besenbacher S, Sulem P, Gudbjartsson DF, Olafsson I, Arinbjarnarson S, Agnarsson BA, Benediktsdottir KR, Isaksson HJ, Kostic JP, Gudjonsson SA, Stacey SN, Gylfason A, Sigurdsson A, Holm H, ... Neal DE, et al. Genetic correction of PSA values using sequence variants associated with PSA levels. Science Translational Medicine. 2: 62ra92. PMID 21160077 DOI: 10.1126/scitranslmed.3001513  0.381
2010 Lane JA, Hamdy FC, Martin RM, Turner EL, Neal DE, Donovan JL. Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies. European Journal of Cancer (Oxford, England : 1990). 46: 3095-101. PMID 21047592 DOI: 10.1016/j.ejca.2010.09.016  0.55
2010 Lewis SJ, Murad A, Chen L, Davey Smith G, Donovan J, Palmer T, Hamdy F, Neal D, Lane JA, Davis M, Cox A, Martin RM. Associations between an obesity related genetic variant (FTO rs9939609) and prostate cancer risk. Plos One. 5: e13485. PMID 20976066 DOI: 10.1371/journal.pone.0013485  0.418
2010 Whitaker HC, Kote-Jarai Z, Ross-Adams H, Warren AY, Burge J, George A, Bancroft E, Jhavar S, Leongamornlert D, Tymrakiewicz M, Saunders E, Page E, Mitra A, Mitchell G, Lindeman GJ, ... Neal DE, et al. The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine. Plos One. 5: e13363. PMID 20967219 DOI: 10.1371/Journal.Pone.0013363  0.452
2010 Collin SM, Metcalfe C, Refsum H, Lewis SJ, Smith GD, Cox A, Davis M, Marsden G, Johnston C, Lane JA, Donovan JL, Neal DE, Hamdy FC, Smith AD, Martin RM. Associations of folate, vitamin B12, homocysteine, and folate-pathway polymorphisms with prostate-specific antigen velocity in men with localized prostate cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 19: 2833-8. PMID 20852008 DOI: 10.1158/1055-9965.EPI-10-0582  0.487
2010 Vickers AJ, Cronin AM, Roobol MJ, Hugosson J, Jones JS, Kattan MW, Klein E, Hamdy F, Neal D, Donovan J, Parekh DJ, Ankerst D, Bartsch G, Klocker H, Horninger W, et al. The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 4374-81. PMID 20736330 DOI: 10.1158/1078-0432.Ccr-10-1328  0.505
2010 Rowlands MA, Holly JM, Gunnell D, Gilbert R, Donovan J, Lane JA, Marsden G, Collin SM, Hamdy F, Neal DE, Martin RM. The relation between adiposity throughout the life course and variation in IGFs and IGFBPs: evidence from the ProtecT (Prostate testing for cancer and Treatment) study. Cancer Causes & Control : Ccc. 21: 1829-42. PMID 20652394 DOI: 10.1007/s10552-010-9610-x  0.385
2010 Neal DE. PSA testing for prostate cancer improves survival-but can we do better? The Lancet Oncology. 11: 702-703. PMID 20598635 DOI: 10.1016/S1470-2045(10)70152-2  0.482
2010 Elliott KS, Zeggini E, McCarthy MI, Gudmundsson J, Sulem P, Stacey SN, Thorlacius S, Amundadottir L, Grönberg H, Xu J, Gaborieau V, Eeles RA, Neal DE, Donovan JL, Hamdy FC, et al. Evaluation of association of HNF1B variants with diverse cancers: collaborative analysis of data from 19 genome-wide association studies. Plos One. 5: e10858. PMID 20526366 DOI: 10.1371/Journal.Pone.0010858  0.42
2010 Collin SM, Metcalfe C, Refsum H, Lewis SJ, Zuccolo L, Smith GD, Chen L, Harris R, Davis M, Marsden G, Johnston C, Lane JA, Ebbing M, Bønaa KH, NygÃ¥rd O, ... Neal DE, et al. Circulating folate, vitamin B12, homocysteine, vitamin B12 transport proteins, and risk of prostate cancer: a case-control study, systematic review, and meta-analysis. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 19: 1632-42. PMID 20501771 DOI: 10.1158/1055-9965.Epi-10-0180  0.359
2010 Lyratzopoulos G, Barbiere JM, Greenberg DC, Wright KA, Neal DE. Population based time trends and socioeconomic variation in use of radiotherapy and radical surgery for prostate cancer in a UK region: continuous survey. Bmj (Clinical Research Ed.). 340: c1928. PMID 20413566 DOI: 10.1136/bmj.c1928  0.468
2010 Macefield RC, Metcalfe C, Lane JA, Donovan JL, Avery KN, Blazeby JM, Down L, Neal DE, Hamdy FC, Vedhara K. Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy result. British Journal of Cancer. 102: 1335-40. PMID 20372151 DOI: 10.1038/sj.bjc.6605648  0.486
2010 Kote-Jarai Z, Leongamornlert D, Tymrakiewicz M, Field H, Guy M, Al Olama AA, Morrison J, O'Brien L, Wilkinson R, Hall A, Sawyer E, Muir K, Hamdy F, Donovan J, Neal D, et al. Mutation analysis of the MSMB gene in familial prostate cancer. British Journal of Cancer. 102: 414-8. PMID 19997100 DOI: 10.1038/sj.bjc.6605485  0.403
2010 Whitaker HC, Warren AY, Eeles R, Kote-Jarai Z, Neal DE. The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic target. The Prostate. 70: 333-40. PMID 19790236 DOI: 10.1002/pros.21059  0.41
2010 Tilling K, Garmo H, Metcalfe C, Holmberg L, Hamdy FC, Neal DE, Adolfsson J, Martin RM, Davis M, Fall K, Lane JA, Adami HO, Bill-Axelson A, Johansson JE, Donovan JL. Development of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: a comparison of observational cohorts. European Urology. 57: 446-52. PMID 19303695 DOI: 10.1016/j.eururo.2009.03.023  0.49
2010 Parry M, Elliott G, Abo R, Camp NJ, Neal DE, Donovan JL, Hamdy FC, Cox A. Abstract 2843: Caspase-8 gene SNPs in prostate cancer susceptibility: a replication study Cancer Research. 70: 2843-2843. DOI: 10.1158/1538-7445.Am10-2843  0.433
2010 Massie C, Lynch A, Stark R, Ramos-Montoya A, Fazli L, Warren A, Scott H, Bon H, Sharma N, Zecchini V, Matthews N, Osborne M, Hadfield J, Swatton J, McArthur S, ... ... Neal D, et al. Abstract 1714: Transcriptional networks downstream of the AR identify clinically relevant prostate cancer targets Cancer Research. 70: 1714-1714. DOI: 10.1158/1538-7445.Am10-1714  0.373
2010 Rowlands M, Holly J, Gunnell D, Donovan J, Lane J, Hamdy F, Neal D, Martin R. OR13,77 Insulin-like growth factors (IGFs) and IGF binding proteins in PSA-detected prostate cancer: a population-based case control study Growth Hormone & Igf Research. 20: S34-S35. DOI: 10.1016/S1096-6374(10)70093-9  0.328
2010 Wong L, Neal DE. Where are we now with prostate cancer diagnosis? Trends in Urology & Men's Health. 1: 18-20. DOI: 10.1002/TRE.158  0.518
2009 Sharma NL, Shah NC, Neal DE. Robotic-assisted laparoscopic prostatectomy. British Journal of Cancer. 101: 1491-6. PMID 19861995 DOI: 10.1038/sj.bjc.6605341  0.349
2009 Chen L, Davey Smith G, Evans DM, Cox A, Lawlor DA, Donovan J, Yuan W, Day IN, Martin RM, Lane A, Rodriguez S, Davis M, Zuccolo L, Collin SM, Hamdy F, Neal D, et al. Genetic variants in the vitamin d receptor are associated with advanced prostate cancer at diagnosis: findings from the prostate testing for cancer and treatment study and a systematic review. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 18: 2874-81. PMID 19861519 DOI: 10.1158/1055-9965.EPI-09-0544  0.474
2009 Eeles RA, Kote-Jarai Z, Al Olama AA, Giles GG, Guy M, Severi G, Muir K, Hopper JL, Henderson BE, Haiman CA, Schleutker J, Hamdy FC, Neal DE, Donovan JL, Stanford JL, et al. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nature Genetics. 41: 1116-21. PMID 19767753 DOI: 10.1038/Ng.450  0.401
2009 Al Olama AA, Kote-Jarai Z, Giles GG, Guy M, Morrison J, Severi G, Leongamornlert DA, Tymrakiewicz M, Jhavar S, Saunders E, Hopper JL, Southey MC, Muir KR, English DR, Dearnaley DP, ... Neal DE, et al. Multiple loci on 8q24 associated with prostate cancer susceptibility. Nature Genetics. 41: 1058-60. PMID 19767752 DOI: 10.1038/ng.452  0.393
2009 Neal DE, Donovan JL, Martin RM, Hamdy FC. Screening for prostate cancer remains controversial. Lancet. 374: 1482-3. PMID 19664817 DOI: 10.1016/S0140-6736(09)61085-0  0.512
2009 Metcalfe C, Tilling K, Davis M, Lane JA, Martin RM, Kynaston H, Powell P, Neal DE, Hamdy F, Donovan JL. Current strategies for monitoring men with localised prostate cancer lack a strong evidence base: observational longitudinal study. British Journal of Cancer. 101: 390-4. PMID 19603015 DOI: 10.1038/sj.bjc.6605181  0.491
2009 Pashayan N, Pharoah P, Neal DE, Hamdy F, Donovan J, Martin RM, Greenberg D, Duffy SW. Stage shift in PSA-detected prostate cancers - effect modification by Gleason score. Journal of Medical Screening. 16: 98-101. PMID 19564523 DOI: 10.1258/jms.2009.009037  0.46
2009 Moore AL, Dimitropoulou P, Lane A, Powell PH, Greenberg DC, Brown CH, Donovan JL, Hamdy FC, Martin RM, Neal DE. Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer. Bju International. 104: 1592-8. PMID 19549125 DOI: 10.1111/j.1464-410X.2009.08652.x  0.481
2009 Collin SM, Metcalfe C, Donovan JL, Athene Lane J, Davis M, Neal DE, Hamdy FC, Martin RM. Associations of sexual dysfunction symptoms with PSA-detected localised and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study. European Journal of Cancer (Oxford, England : 1990). 45: 3254-61. PMID 19541477 DOI: 10.1016/j.ejca.2009.05.021  0.473
2009 Unoki M, Kelly JD, Neal DE, Ponder BAJ, Nakamura Y, Hamamoto R. UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer British Journal of Cancer. 101: 98-105. PMID 19491893 DOI: 10.1038/sj.bjc.6605123  0.348
2009 Murad A, Lewis SJ, Smith GD, Collin SM, Chen L, Hamdy FC, Neal DE, Donovan J, Martin RM. PTGS2-899G>C and prostate cancer risk: a population-based nested case-control study (ProtecT) and a systematic review with meta-analysis. Prostate Cancer and Prostatic Diseases. 12: 296-300. PMID 19488068 DOI: 10.1038/pcan.2009.18  0.392
2009 Turner EL, Lane JA, Metcalfe C, Down L, Donovan JL, Hamdy F, Neal D, Vedhara K. Psychological distress and prostate specific antigen levels in men with and without prostate cancer. Brain, Behavior, and Immunity. 23: 1073-8. PMID 19486654 DOI: 10.1016/j.bbi.2009.01.009  0.505
2009 Gilbert R, Metcalfe C, Oliver SE, Whiteman DC, Bain C, Ness A, Donovan J, Hamdy F, Neal DE, Lane JA, Martin RM. Life course sun exposure and risk of prostate cancer: population-based nested case-control study and meta-analysis. International Journal of Cancer. Journal International Du Cancer. 125: 1414-23. PMID 19444909 DOI: 10.1002/ijc.24411  0.495
2009 Macefield RC, Lane JA, Metcalfe C, Down L, Neal DE, Hamdy FC, Donovan JL. Do the risk factors of age, family history of prostate cancer or a higher prostate specific antigen level raise anxiety at prostate biopsy? European Journal of Cancer (Oxford, England : 1990). 45: 2569-73. PMID 19375907 DOI: 10.1016/j.ejca.2009.03.016  0.464
2009 Pashayan N, Duffy SW, Pharoah P, Greenberg D, Donovan J, Martin RM, Hamdy F, Neal DE. Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening. British Journal of Cancer. 100: 1198-204. PMID 19293796 DOI: 10.1038/sj.bjc.6604973  0.404
2009 Oliver RT, Neal DE. Treatment for PSA screen-detected prostate cancer: what are the options? Nature Clinical Practice. Urology. 6: 132-4. PMID 19174774 DOI: 10.1038/ncpuro1297  0.481
2009 Guy M, Kote-Jarai Z, Giles GG, Al Olama AA, Jugurnauth SK, Mulholland S, Leongamornlert DA, Edwards SM, Morrison J, Field HI, Southey MC, Severi G, Donovan JL, Hamdy FC, Dearnaley DP, ... Neal DE, et al. Identification of new genetic risk factors for prostate cancer. Asian Journal of Andrology. 11: 49-55. PMID 19050691 DOI: 10.1038/aja.2008.18  0.328
2009 Lane J, Donovan J, Neal D, Hamdy F. 961 THE PROTECT TRIAL - EVALUATING THE EFFECTIVENESS OF TREATMENTS FOR CLINICALLY LOCALISED PROSTATE CANCER European Urology Supplements. 8: 361. DOI: 10.1016/S1569-9056(09)60946-5  0.482
2009 Collin S, Metcalfe C, Donovan J, Lane J, Neal D, Hamdy F, Davis M, Martin R. 74 ASSOCIATIONS OF SEXUAL DYSFUNCTION WITH LOCALIZED AND ADVANCED PROSTATE CANCER: A CASE-CONTROL STUDY NESTED WITHIN THE UK POPULATION-BASED PROTECT (PROSTATE TESTING FOR CANCER AND TREATMENT) STUDY European Urology Supplements. 8: 139. DOI: 10.1016/S1569-9056(09)60080-4  0.484
2009 Neal DE, McLoughlin J, Anderson JB, Fawcett DP, Kockelbergh RC. Clarification of NICE Guidance on Prostate Cancer British Journal of Medical and Surgical Urology. 2: 219-223. DOI: 10.1016/j.bjmsu.2009.09.001  0.536
2008 Zuccolo L, Harris R, Gunnell D, Oliver S, Lane JA, Davis M, Donovan J, Neal D, Hamdy F, Beynon R, Savovic J, Martin RM. Height and prostate cancer risk: a large nested case-control study (ProtecT) and meta-analysis. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 17: 2325-36. PMID 18768501 DOI: 10.1158/1055-9965.EPI-08-0342  0.468
2008 Avery KN, Metcalfe C, Blazeby JM, Lane JA, Neal DE, Hamdy FC, Donovan JL. Prostate-specific antigen testing and prostate biopsy: are self-reported lower urinary tract symptoms and health-related quality of life associated with the decision to undergo these investigations? Bju International. 102: 1629-33. PMID 18710456 DOI: 10.1111/j.1464-410X.2008.07879.x  0.382
2008 Kote-Jarai Z, Easton DF, Stanford JL, Ostrander EA, Schleutker J, Ingles SA, Schaid D, Thibodeau S, Dörk T, Neal D, Donovan J, Hamdy F, Cox A, Maier C, Vogel W, et al. Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 17: 2052-61. PMID 18708398 DOI: 10.1158/1055-9965.Epi-08-0317  0.36
2008 Neal DE. Can We Accurately Identify Men With Low Risk Prostate Cancer? Journal of Urology. 180: 1217-1218. PMID 18707718 DOI: 10.1016/j.juro.2008.07.086  0.492
2008 Ghoussaini M, Song H, Koessler T, Al Olama AA, Kote-Jarai Z, Driver KE, Pooley KA, Ramus SJ, Kjaer SK, Hogdall E, DiCioccio RA, Whittemore AS, Gayther SA, Giles GG, Guy M, ... Neal DE, et al. Multiple loci with different cancer specificities within the 8q24 gene desert. Journal of the National Cancer Institute. 100: 962-6. PMID 18577746 DOI: 10.1093/Jnci/Djn190  0.389
2008 Collin SM, Metcalfe C, Donovan J, Lane JA, Davis M, Neal D, Hamdy F, Martin RM. Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screen-detected localized and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study. Bju International. 102: 1400-6. PMID 18540932 DOI: 10.1111/j.1464-410X.2008.07817.x  0.503
2008 Vias M, Massie CE, East P, Scott H, Warren A, Zhou Z, Nikitin AY, Neal DE, Mills IG. Pro-neural transcription factors as cancer markers. Bmc Medical Genomics. 1: 17. PMID 18489756 DOI: 10.1186/1755-8794-1-17  0.353
2008 Whitaker HC, Girling J, Warren AY, Leung H, Mills IG, Neal DE. Alterations in beta-catenin expression and localization in prostate cancer. The Prostate. 68: 1196-205. PMID 18459111 DOI: 10.1002/pros.20780  0.318
2008 Collin SM, Martin RM, Metcalfe C, Gunnell D, Albertsen PC, Neal D, Hamdy F, Stephens P, Lane JA, Moore R, Donovan J. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. The Lancet. Oncology. 9: 445-52. PMID 18424233 DOI: 10.1016/S1470-2045(08)70104-9  0.521
2008 Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, Guy M, Jugurnauth SK, Mulholland S, Leongamornlert DA, Edwards SM, Morrison J, Field HI, Southey MC, Severi G, Donovan JL, Hamdy FC, ... Neal DE, et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nature Genetics. 40: 316-21. PMID 18264097 DOI: 10.1038/ng.90  0.503
2008 Aitchison AA, Veerakumarasivam A, Vias M, Kumar R, Hamdy FC, Neal DE, Mills IG. Promoter methylation correlates with reduced Smad4 expression in advanced prostate cancer. The Prostate. 68: 661-74. PMID 18213629 DOI: 10.1002/pros.20730  0.318
2008 Hussain S, Gunnell D, Donovan J, McPhail S, Hamdy F, Neal D, Albertsen P, Verne J, Stephens P, Trotter C, Martin RM. Secular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975-2004. Bju International. 101: 547-55. PMID 18190630 DOI: 10.1111/j.1464-410X.2007.07338.x  0.516
2008 Rosario DJ, Lane JA, Metcalfe C, Catto JW, Dedman D, Donovan JL, Neal DE, Hamdy FC. Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT study. European Urology. 53: 777-84. PMID 18079051 DOI: 10.1016/j.eururo.2007.11.064  0.525
2008 Avery KN, Blazeby JM, Lane JA, Neal DE, Hamdy FC, Donovan JL. Decision-making about PSA testing and prostate biopsies: a qualitative study embedded in a primary care randomised trial. European Urology. 53: 1186-93. PMID 17709169 DOI: 10.1016/j.eururo.2007.07.040  0.372
2008 Davis M, Lane J, Gilbert R, Martin R, Donovan J, Neal D, Hamdy F. RAISED BLOOD PRESSURE PREDICTS PROSTATE CANCER AND ELEVATED PSA IN A LARGE UNSELECTED POPULATION OF MEN PARTICIPATING IN THE PROTECT STUDY European Urology Supplements. 7: 198. DOI: 10.1016/S1569-9056(08)60505-9  0.415
2008 Chen L, Smith G, Donovan J, Neal D, Hamdy F, Cox A, Day I, Rodriguez S, Davis M, Lewis S. Effect of vitamin D receptor gene on prostate cancer progression: genetic association study and meta-analysis European Journal of Cancer Supplements. 6: 201. DOI: 10.1016/S1359-6349(08)71891-3  0.388
2007 Lane JA, Howson J, Donovan JL, Goepel JR, Dedman DJ, Down L, Turner EL, Neal DE, Hamdy FC. Detection of prostate cancer in unselected young men: prospective cohort nested within a randomised controlled trial. Bmj (Clinical Research Ed.). 335: 1139. PMID 18006969 DOI: 10.1136/bmj.39381.436829.BE  0.509
2007 Aitchison A, Warren A, Neal D, Rabbitts P. RASSF1A promoter methylation is frequently detected in both pre-malignant and non-malignant microdissected prostatic epithelial tissues. The Prostate. 67: 638-44. PMID 17342751 DOI: 10.1002/pros.20475  0.379
2007 Vias M, Burtt G, Culig Z, Veerakumarasivam A, Neal DE, Mills IG. A role for neurotensin in bicalutamide resistant prostate cancer cells. The Prostate. 67: 190-202. PMID 17044078 DOI: 10.1002/PROS.20518  0.421
2007 Lane J, Donovan J, Neal D, Hamdy F. 637 THE PROTECT TRIAL - EVALUATING THE EFFECTIVENESS OF TREATMENTS FOR CLINICALLY LOCALISED PROSTATE CANCER AND ASSOCIATED MOLECULAR AND GENETIC EPIDEMIOLOGY STUDIES European Urology Supplements. 6: 182. DOI: 10.1016/S1569-9056(07)60635-6  0.447
2006 Metcalfe C, Lane JA, Hamdy F, Neal D, Donovan JL. A model of the natural history of screen-detected prostate cancer. British Journal of Cancer. 95: 1122-3. PMID 17003784 DOI: 10.1038/sj.bjc.6603368  0.472
2006 Brindle LA, Oliver SE, Dedman D, Donovan JL, Neal DE, Hamdy FC, Lane JA, Peters TJ. Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK. Bju International. 98: 777-82. PMID 16978272 DOI: 10.1111/j.1464-410X.2006.06401.x  0.444
2006 Martin RM, Gunnell D, Hamdy F, Neal D, Lane A, Donovan J. Continuing controversy over monitoring men with localized prostate cancer: a systematic review of programs in the prostate specific antigen era. The Journal of Urology. 176: 439-49. PMID 16813862 DOI: 10.1016/J.JURO.2006.03.030  0.498
2006 Donovan JL, Martin RM, Neal DE, Hamdy FC. Prostate cancer: screening approaches. British Journal of Hospital Medicine (London, England : 2005). 66: 623-6. PMID 16308948 DOI: 10.12968/HMED.2005.66.11.20023  0.504
2006 Lane A, Howson J, Mason M, Neal D, Donovan J, Hamdy F. PROSTATE CANCER DETECTION IN MEN AGED 45-49 YEARS IN THE UK PROTECT (PROSTATE TESTING FOR CANCER AND TREATMENT) TRIAL European Urology Supplements. 5: 318. DOI: 10.1016/S1569-9056(06)61185-8  0.518
2006 Hamdy FC, Howson J, Lane A, Donovan JL, Neal DE. 1476: Prostate Cancer Detection in Men Aged 45-49 Years in the UK Protect (Prostate Testing for Cancer and Treatment) Trial Journal of Urology. 175: 476-477. DOI: 10.1016/s0022-5347(18)33680-2  0.518
2006 Neal DE, Moore A, Hamdy FC, Donovan JL, Lane A. 525: The Protect (Prostate Testing for Cancer and Treatment) Study: Advanced Cases Found Through a UK Screening Study Journal of Urology. 175: 170-170. DOI: 10.1016/S0022-5347(18)32771-X  0.462
2006 Hamdy FC, Dedman D, Lane A, Oliver S, Powell P, Leung H, Gillatt D, Neal DE, Donovan JL. 472: The Value of Repeat Serum PSA Measurements in the Detection of Prostate Cancer - Experience from the Feasibility Phase of the UK Protect Study Journal of Urology. 175: 153-153. DOI: 10.1016/S0022-5347(18)32728-9  0.432
2005 Donovan JL, Hamdy FC, Neal DE. Screening for prostate cancer. The case against. Annals of the Royal College of Surgeons of England. 87: 90-1; discussion 88. PMID 15832433  0.488
2005 Hamdy F, Dedman D, Lane A, Oliver S, Powell P, Leung H, Gillatt D, Neal D, Donovan J. 597The value of repeat serum PSA measurements in the detection of prostate cancer — Experience from the UK protect study European Urology Supplements. 4: 152. DOI: 10.1016/S1569-9056(05)80601-3  0.457
2004 Oliver SE, Holly J, Peters TJ, Donovan J, Persad R, Gillatt D, Pearce A, Hamdy FC, Neal DE, Gunnell D. Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening. Urology. 64: 317-22. PMID 15302487 DOI: 10.1016/j.urology.2004.03.018  0.414
2004 Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT. CD133, a novel marker for human prostatic epithelial stem cells. Journal of Cell Science. 117: 3539-45. PMID 15226377 DOI: 10.1242/jcs.01222  0.309
2004 Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN. Upregulation and Nuclear Recruitment of HDACl in Hormone Refractory Prostate Cancer Prostate. 59: 177-189. PMID 15042618 DOI: 10.1002/pros.20022  0.407
2004 Halkidou K, Cook S, Leung HY, Neal DE, Robson CN. Nuclear accumulation of histone deacetylase 4 (HDAC4) coincides with the loss of androgen sensitivity in hormone refractory cancer of the prostate. European Urology. 45: 382-9; author reply . PMID 15036687 DOI: 10.1016/J.EURURO.2003.10.005  0.436
2004 Oliver SE, Barrass B, Gunnell DJ, Donovan JL, Peters TJ, Persad RA, Gillatt D, Neal DE, Hamdy FC, Holly JM. Serum insulin-like growth factor-I is positively associated with serum prostate-specific antigen in middle-aged men without evidence of prostate cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 13: 163-5. PMID 14744750 DOI: 10.1158/1055-9965.EPI-03-0102  0.485
2004 Oliver SE, Gunnell D, Donovan J, Peters TJ, Persad R, Gillatt D, Pearce A, Neal DE, Hamdy FC, Holly J. Screen-detected prostate cancer and the insulin-like growth factor axis: results of a population-based case-control study. International Journal of Cancer. 108: 887-92. PMID 14712493 DOI: 10.1002/ijc.11631  0.43
2004 Neal DE, Hegarty P. Key questions in benign prostatic hyperplasia. The Practitioner. 247: 886-9. PMID 14640052  0.434
2003 Donovan JL, Peters TJ, Noble S, Powell P, Gillatt D, Oliver SE, Lane JA, Neal DE, Hamdy FC. Who can best recruit to randomized trials? Randomized trial comparing surgeons and nurses recruiting patients to a trial of treatments for localized prostate cancer (the ProtecT study). Journal of Clinical Epidemiology. 56: 605-9. PMID 12921927 DOI: 10.1016/S0895-4356(03)00083-0  0.351
2003 Hamdy FC, Donovan JL, Lane JA, Neal DE. Ethics of clinical trials from bayesian perspective: randomisation to clinical trials may solve dilemma of treatment choice in prostate cancer. Bmj (Clinical Research Ed.). 326: 1456. PMID 12829565 DOI: 10.1136/bmj.326.7404.1456  0.397
2003 Halkidou K, Gnanapragasam VJ, Mehta PB, Logan IR, Brady ME, Cook S, Leung HY, Neal DE, Robson CN. Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene. 22: 2466-77. PMID 12717424 DOI: 10.1038/sj.onc.1206342  0.449
2003 Frankel S, Smith GD, Donovan J, Neal D. Screening for prostate cancer. Lancet (London, England). 361: 1122-8. PMID 12672328 DOI: 10.1016/S0140-6736(03)12890-5  0.481
2003 Drake MJ, Robson W, Mehta P, Schofield I, Neal DE, Leung HY. An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. British Journal of Cancer. 88: 822-7. PMID 12644816 DOI: 10.1038/sj.bjc.6600817  0.39
2003 Mehta PB, Jenkins BL, McCarthy L, Thilak L, Robson CN, Neal DE, Leung HY. MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion. Oncogene. 22: 1381-9. PMID 12618764 DOI: 10.1038/sj.onc.1206154  0.443
2003 Oliver SE, Donovan JL, Peters TJ, Frankel S, Hamdy FC, Neal DE. Recent trends in the use of radical prostatectomy in England: the epidemiology of diffusion. Bju International. 91: 331-6; discussion 33. PMID 12603408 DOI: 10.1046/j.1464-410X.2003.04083.x  0.368
2003 Gnanapragasam V, Robinson M, Robson C, Hamdy F, Neal D, Leung H. Overexpression of FGF8B in advanced stage and high grade prostate cancer European Urology Supplements. 2: 162. DOI: 10.1016/S1569-9056(03)80639-5  0.479
2003 Barrass B, Persad R, Gillatt D, Neal D, Hamdy F, Oliver S, Gunnell D, Donovan J, Peters T, Holly J. IGF, PSA, glandular hyperplasia and cancer risk in the prostate European Urology Supplements. 2: 83. DOI: 10.1016/S1569-9056(03)80327-5  0.5
2002 Noble SM, Coast J, Brookes S, Neal DE, Abrams P, Peters TJ, Donovan JL. Transurethral prostate resection, noncontact laser therapy or conservative management in men with symptoms of benign prostatic enlargement? An economic evaluation. The Journal of Urology. 168: 2476-82. PMID 12441944 DOI: 10.1097/01.ju.0000035182.81727.be  0.382
2002 Donovan J, Mills N, Smith M, Brindle L, Jacoby A, Peters T, Frankel S, Neal D, Hamdy F. Quality improvement report: Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. Commentary: presenting unbiased information to patients can be difficult. Bmj (Clinical Research Ed.). 325: 766-70. PMID 12364308 DOI: 10.1136/bmj.325.7367.766  0.358
2002 Gnanapragasam VJ, Robson CN, Neal DE, Leung HY. Regulation of FGF8 expression by the androgen receptor in human prostate cancer. Oncogene. 21: 5069-80. PMID 12140757 DOI: 10.1038/sj.onc.1205663  0.423
2002 Neal DE, Donovan JL. Prostate cancer: to screen or not to screen? The Lancet. Oncology. 1: 17-24. PMID 11905682 DOI: 10.1016/S1470-2045(00)00005-X  0.476
2002 Gnanapragasam VJ, Leung HY, Pulimood AS, Neal DE, Robson CN. Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer. British Journal of Cancer. 85: 1928-36. PMID 11747336 DOI: 10.1054/bjoc.2001.2179  0.411
2002 Gnanapragasm V, Robson C, Neal D, Leung H. Regulation of Fgf8 Expression by the Androgen Receptor in Human Prostate Cancer Clinical Science. 103: 75P-75P. DOI: 10.1042/CS103075P  0.447
2002 Drake M, Robson W, Neal DE, Leung HY. Low dose thalidomide in androgen independent prostate cancer European Urology Supplements. 1: 159. DOI: 10.1016/S1569-9056(02)80620-0  0.482
2002 Douglas D, Mehta P, Neal D, Leung H. Quantitation of human sprouty-2 (a novel inhibitor of fibroblast growth factor receptors) in human prostate cancer European Urology Supplements. 1: 32. DOI: 10.1016/S1569-9056(02)80117-8  0.389
2002 NOBLE SM, COAST J, BROOKES S, NEAL DE, ABRAMS P, PETERS TJ, DONOVAN JL. Transurethral Prostate Resection, Noncontact Laser Therapy or Conservative Management in Men With Symptoms of Benign Prostatic Enlargement? An Economic Evaluation Journal of Urology. 168: 2476-2482. DOI: 10.1016/S0022-5347(05)64172-9  0.371
2001 Donovan JL, Frankel SJ, Neal DE, Hamdy FC. Screening for prostate cancer in the UK. Seems to be creeping in by the back door. Bmj (Clinical Research Ed.). 323: 763-4. PMID 11588064 DOI: 10.1136/bmj.323.7316.763  0.503
2001 Mehta PB, Robson CN, Neal DE, Leung HY. Keratinocyte growth factor activates p38 MAPK to induce stress fibre formation in human prostate DU145 cells. Oncogene. 20: 5359-65. PMID 11536048 DOI: 10.1038/sj.onc.1204688  0.311
2001 Gnanapragasam VJ, Robson CN, Leung HY, Neal DE. Androgen receptor signalling in the prostate. Bju International. 86: 1001-13. PMID 11119093 DOI: 10.1046/j.1464-410x.2000.00943.x  0.377
2001 CRESSWELL J, ROBERTS J, NEAL D. URETHRAL RECURRENCE AFTER RADICAL RADIOTHERAPY FOR BLADDER CANCER Journal of Urology. 165: 1135-1137. DOI: 10.1016/S0022-5347(05)66449-X  0.314
2001 CHACKO KN, DONOVAN JL, ABRAMS P, PETERS TJ, BROOKES ST, THORPE AC, GUJRAL S, WRIGHT M, KENNEDY LG, NEAL DE. TRANSURETHRAL PROSTATIC RESECTION OR LASER THERAPY FOR MEN WITH ACUTE URINARY RETENTION: THE CLASP RANDOMIZED TRIAL Journal of Urology. 166: 166-171. DOI: 10.1016/S0022-5347(05)66101-0  0.34
2000 Gnanapragasam VJ, McCahy PJ, Neal DE, Robson CN. Insulin-like growth factor II and androgen receptor expression in the prostate. Bju International. 86: 731-5. PMID 11069386 DOI: 10.1046/j.1464-410x.2000.00874.x  0.307
2000 Mehta P, Robson CN, Neal DE, Leung HY. Fibroblast growth factor receptor-2 mutation analysis in human prostate cancer. Bju International. 86: 681-5. PMID 11069376 DOI: 10.1046/j.1464-410x.2000.00893.x  0.459
2000 Karayi MK, Neal DE, Markham AF. Current status of linkage studies in hereditary prostate cancer. Bju International. 86: 659-69. PMID 11069373 DOI: 10.1046/j.1464-410x.2000.00837.x  0.51
2000 Neal DE, Leung HY, Powell PH, Hamdy FC, Donovan JL. Unanswered questions in screening for prostate cancer. European Journal of Cancer (Oxford, England : 1990). 36: 1316-21. PMID 10882874 DOI: 10.1016/S0959-8049(00)00104-0  0.528
2000 Thorpe AC, Neal DE. Patient information and consent in trials for the treatment of benign prostatic obstruction. Bju International. 85: 42-5. PMID 10756705 DOI: 10.1046/j.1464-410x.2000.00042.x  0.383
2000 DONOVAN JL, PETERS TJ, NEAL DE, BROOKES ST, GUJRAL S, CHACKO KN, WRIGHT M, KENNEDY LG, ABRAMS P. A RANDOMIZED TRIAL COMPARING TRANSURETHRAL RESECTION OF THE PROSTATE, LASER THERAPY AND CONSERVATIVE TREATMENT OF MEN WITH SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC ENLARGEMENT: THE CLasP STUDY Journal of Urology. 164: 65-70. DOI: 10.1016/S0022-5347(05)67450-2  0.407
2000 GUJRAL S, ABRAMS P, DONOVAN J, NEAL D, BROOKES S, CHACKO K, WRIGHT M, TIMONEY A, PETERS T. A PROSPECTIVE RANDOMIZED TRIAL COMPARING TRANSURETHRAL RESECTION OF THE PROSTATE AND LASER THERAPY IN MEN WITH CHRONIC URINARY RETENTION: THE CLasP STUDY Journal of Urology. 164: 59-64. DOI: 10.1016/S0022-5347(05)67449-6  0.342
2000 MEHTA P, ROBSON C, NEAL D, LEUNG H. SERUM KERATINOCYTE GROWTH FACTOR MEASUREMENT IN PATIENTS WITH PROSTATE CANCER Journal of Urology. 164: 2151-2155. DOI: 10.1016/S0022-5347(05)66988-1  0.44
1999 Dorkin TJ, Robinson MC, Marsh C, Neal DE, Leung HY. aFGF immunoreactivity in prostate cancer and its co-localization with bFGF and FGF8. The Journal of Pathology. 189: 564-9. PMID 10629559 DOI: 10.1002/(SICI)1096-9896(199912)189:4<564::AID-PATH480>3.0.CO;2-1  0.508
1999 Dorkin TJ, Robinson MC, Marsh C, Bjartell A, Neal DE, Leung HY. FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease. Oncogene. 18: 2755-61. PMID 10348350 DOI: 10.1038/sj.onc.1202624  0.48
1998 Neal DE. Screening for prostate cancer Annals of Oncology. 9: 1289-1292. PMID 9932157 DOI: 10.1023/A:1008487912288  0.508
1998 Johnson MI, Robinson MC, Marsh C, Robson CN, Neal DE, Hamdy FC. Expression of Bcl-2, Bax, and p53 in high-grade prostatic intraepithelial neoplasia and localized prostate cancer: relationship with apoptosis and proliferation. The Prostate. 37: 223-9. PMID 9831218 DOI: 10.1002/(SICI)1097-0045(19981201)37:4<223::AID-PROS3>3.0.CO;2-O  0.501
1998 Autzen P, Robson CN, Bjartell A, Malcolm AJ, Johnson MI, Neal DE, Hamdy FC. Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies. British Journal of Cancer. 78: 1219-23. PMID 9820184 DOI: 10.1038/bjc.1998.658  0.382
1998 Betts AM, Collett GP, Neal DE, Robson CN. Paracrine regulation of talin mRNA expression by androgen in human prostate. Febs Letters. 434: 66-70. PMID 9738453 DOI: 10.1016/S0014-5793(98)00953-3  0.422
1998 Chakrabarti P, Orihuela E, Egger N, Neal DE, Gangula R, Adesokun A, Motamedi M. Delta-aminolevulinic acid-mediated photosensitization of prostate cell lines: implication for photodynamic therapy of prostate cancer. The Prostate. 36: 211-8. PMID 9719020 DOI: 10.1002/(SICI)1097-0045(19980901)36:4<211::AID-PROS1>3.0.CO;2-I  0.436
1998 Naguib RN, Robinson MC, Neal DE, Hamdy FC. Neural network analysis of combined conventional and experimental prognostic markers in prostate cancer: a pilot study. British Journal of Cancer. 78: 246-50. PMID 9683301 DOI: 10.1038/bjc.1998.472  0.421
1998 Griffiths TR, Neal DE. Localized prostate cancer: early intervention or expectant therapy? Journal of the Royal Society of Medicine. 90: 665-9. PMID 9496291 DOI: 10.1177/014107689709001208  0.439
1998 Dorkin TJ, Robson CN, Neal DE. The molecular pathology of urological malignancies. The Journal of Pathology. 183: 380-7. PMID 9496253 DOI: 10.1002/(SICI)1096-9896(199712)183:4<380::AID-PATH959>3.0.CO;2-7  0.377
1997 Dorkin TJ, Neal DE. Basic science aspects of prostate cancer. Seminars in Cancer Biology. 8: 21-7. PMID 9299578 DOI: 10.1006/SCBI.1997.0049  0.497
1997 Robinson EJ, Collins AT, Robson CN, Neal DE. Effects of a new 5α reductase inhibitor (Epristeride) on human prostate cell cultures Prostate. 32: 259-265. PMID 9288184 DOI: 10.1002/(SICI)1097-0045(19970901)32:4<259::AID-PROS5>3.0.CO;2-E  0.331
1997 Leung HY, Mehta P, Gray LB, Collins AT, Robson CN, Neal DE. Keratinocyte growth factor expression in hormone insensitive prostate cancer Oncogene. 15: 1115-1120. PMID 9285567 DOI: 10.1038/sj.onc.1201256  0.467
1997 Leung HY, Lai LC, Day J, Thomson J, Neal DE, Hamdy FC. Serum free prostate-specific antigen in the diagnosis of prostate cancer. British Journal of Urology. 80: 256-9. PMID 9284198 DOI: 10.1046/J.1464-410X.1997.00230.X  0.488
1997 Betts AM, Waite I, Neal DE, Robson CN. Androgen regulation of ornithine decarboxylase in human prostatic cells identified using differential display. Febs Letters. 405: 328-32. PMID 9108313 DOI: 10.1016/S0014-5793(97)00209-3  0.419
1997 Byrne RL, Horne CH, Robinson MC, Autzen P, Apakama I, Bishop RI, Neal DE, Hamdy FC. The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma. British Journal of Urology. 79: 190-5. PMID 9052469 DOI: 10.1046/J.1464-410X.1997.03399.X  0.38
1997 Leung HY, Griffiths TR, Neal DE. Bladder cancer. Postgraduate Medical Journal. 72: 719-24. PMID 9015464 DOI: 10.1136/pgmj.72.854.719  0.322
1996 McCahy PJ, Harris CA, Neal DE. Breast and prostate cancer in the relatives of men with prostate cancer. British Journal of Urology. 78: 552-6. PMID 8963638 DOI: 10.1046/J.1464-410X.1996.17111.X  0.511
1996 Apakama I, Robinson MC, Walter NM, Charlton RG, Royds JA, Fuller CE, Neal DE, Hamdy FC. bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. British Journal of Cancer. 74: 1258-62. PMID 8883414 DOI: 10.1038/bjc.1996.526  0.351
1996 Byrne RL, Leung H, Neal DE. Peptide growth factors in the prostate as mediators of stromal epithelial interaction. British Journal of Urology. 77: 627-33. PMID 8689101 DOI: 10.1046/J.1464-410X.1996.09721.X  0.418
1996 Neal DE, Hamdy FC. Measurement of prostate specific antigen as screening test for prostate cancer. Paper gives misleadingly optimistic view. Bmj (Clinical Research Ed.). 312: 709; author reply 70. PMID 8597765 DOI: 10.1136/bmj.312.7032.709c  0.495
1996 Oefelein M, Kaul K, Ignatoff J, Herz B, Hamdy FC, Neal DE, Badwe R, Vaidya J. Haematogenous dissemination of prostate epithelial cells during surgery The Lancet. 347: 324-326. PMID 8569378 DOI: 10.1016/S0140-6736(96)90499-7  0.346
1996 Leyshon Griffiths TR, Neal DE. Prognostic markers in bladder cancer Current Opinion in Urology. 6: 267-271. DOI: 10.1097/00042307-199609000-00008  0.316
1996 Neal DE. The morbidity of transurethral resection of the prostate Current Opinion in Urology. 6: 147-150. DOI: 10.1097/00042307-199605000-00008  0.391
1995 Hamdy FC, Neal DE. Detection of prostate cancer. Methods are changing rapidly. Bmj (Clinical Research Ed.). 310: 1140. PMID 7742699 DOI: 10.1136/BMJ.310.6987.1140  0.473
1994 Thorpe AC, Cleary R, Coles J, Vernon S, Reynolds J, Neal DE. Deaths and complications following prostatectomy in 1400 men in the northern region of England. Northern Regional Prostate Audit Group. British Journal of Urology. 74: 559-65. PMID 7530118 DOI: 10.1111/J.1464-410X.1994.TB09184.X  0.335
1994 Neal DE. Transurethral prostatectomy British Journal of Surgery. 81: 484-485. PMID 7515760 DOI: 10.1002/bjs.1800810403  0.358
1994 Feneley M, Kirby R, Parkinson C, Catalona W, Karnauchow P, Neal D, Hamdy F, Schröder F. Screening for prostate cancer The Lancet. 343: 1436-1439. DOI: 10.1016/S0140-6736(94)92566-6  0.508
1992 Harris AL, Neal DE. Bladder cancer - Field versus clonal origin New England Journal of Medicine. 326: 759-761. PMID 1738381 DOI: 10.1056/NEJM199203123261108  0.434
1992 Thompson SJ, Mellon K, Charlton RG, Marsh C, Robinson M, Neal DE. P53 and Ki-67 immunoreactivity in human prostate cancer and benign hyperplasia. British Journal of Urology. 69: 609-13. PMID 1379102 DOI: 10.1111/J.1464-410X.1992.TB15632.X  0.492
1992 Mellon K, Thompson S, Charlton RG, Marsh C, Robinson M, Lane DP, Harris AL, Horne CH, Neal DE. p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. The Journal of Urology. 147: 496-9. PMID 1370701 DOI: 10.1016/S0022-5347(17)37287-7  0.389
1991 Roach MB, George WJ, Figueroa TE, Neal DE, McBride D. Ciprofloxacin versus gentamicin in prophylaxis against bacteremia in transrectal prostate needle biopsy Urology. 38: 84-87. PMID 1866869 DOI: 10.1016/0090-4295(91)80024-2  0.385
1991 Donovan J, Frankel S, Abrams P, Neal D. Prevalence of benign prostatic hypertrophy The Lancet. 338: 1076-1077. DOI: 10.1016/0140-6736(91)91932-K  0.419
1989 Neal DE, Smith K, Fennelly JA, Bennett MK, Hall RR, Harris AL. Epidermal growth factor receptor in human bladder cancer: a comparison of immunohistochemistry and ligand binding. The Journal of Urology. 141: 517-21. PMID 2783984 DOI: 10.1016/S0022-5347(17)40877-9  0.306
1989 Neal DE, Styles RA. Late renal failure due to prostatic outflow obstruction. Bmj (Clinical Research Ed.). 298: 602. PMID 2467712 DOI: 10.1136/BMJ.298.6673.602-B  0.314
1988 Carr TW, Neal DE, Powell PH, Hall RR. Conservative management of prostate cancer Lancet. 1: 776-777. PMID 2895310 DOI: 10.1016/S0140-6736(88)91592-9  0.476
1988 Styles RA, Neal DE, Powell PH. Reproducibility of measurement of prostatic volume by ultrasound. Comparison of transrectal and transabdominal methods. European Urology. 14: 266-9. PMID 2458933 DOI: 10.1159/000472957  0.382
1986 Harris AL, Sainsbury R, Needham G, Neal D, Veale D, Smith K, Hall R, Farndon J, Hirst L. Clinical significance of growth factor receptors in breast and bladder cancer European Journal of Cancer and Clinical Oncology. 22: 726. DOI: 10.1016/0277-5379(86)90212-9  0.38
Show low-probability matches.